



HU000030150T2

(19) **HU**(11) Lajstromszám: **E 030 150**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 764553**(51) Int. Cl.: **C07K 16/28** (2006.01)(22) A bejelentés napja: **2011. 10. 04.****A61K 393/95** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20110764553

(86) A nemzetközi (PCT) bejelentési szám:

PCT/EP 11/067339

(97) Az európai bejelentés közzétételi adatai:

EP 2625201 A1 **2012. 04. 12.**

(87) A nemzetközi közzétételi szám:

WO 12045752

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2625201 B1 **2016. 09. 07.**

(30) Elsőbbségi adatok:

10186468**2010. 10. 04.****EP**

(73) Jogosult(ak):

**Boehringer Ingelheim International GmbH,
55216 Ingelheim am Rhein (DE)**

(72) Feltaláló(k):

KONOPITZKY, Renate, 55216 Ingelheim Am Rhein (DE)**BORGES, Eric, 55216 Ingelheim Am Rhein (DE)****ADAM, Paul, 55216 Ingelheim Am Rhein (DE)****HEIDER, Karl-Heinz, 55216 Ingelheim Am Rhein (DE)**

(74) Képviselő:

**Advopatent Szabadalmi és Védjegy Iroda,
Budapest**

(54)

CD33 kötőágensek

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11)

EP 2 625 201 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
07.09.2016 Bulletin 2016/36

(21) Application number: **11764553.1**

(22) Date of filing: **04.10.2011**

(51) Int Cl.:
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)

(86) International application number:
PCT/EP2011/067339

(87) International publication number:
WO 2012/045752 (12.04.2012 Gazette 2012/15)

(54) **CD33 BINDING AGENTS**

CD33-BINDENDE MITTEL

AGENTS SE LIANT AUX CD33

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **04.10.2010 EP 10186468**

(43) Date of publication of application:
14.08.2013 Bulletin 2013/33

(73) Proprietor: **Boehringer Ingelheim International
GmbH
55216 Ingelheim am Rhein (DE)**

(72) Inventors:
• **KONOPITZKY, Renate
55216 Ingelheim Am Rhein (DE)**
• **BORGES, Eric
55216 Ingelheim Am Rhein (DE)**
• **ADAM, Paul
55216 Ingelheim Am Rhein (DE)**
• **HEIDER, Karl-Heinz
55216 Ingelheim Am Rhein (DE)**

(74) Representative: **Simon, Elke Anna Maria et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein (DE)**

(56) References cited:
WO-A2-2008/058021

- **CARON PHILIP C ET AL: "Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies", CANCER RESEARCH, vol. 52, no. 24, 1992, pages 6761-6767, XP009142412, ISSN: 0008-5472**
- **CARON P C ET AL: "MURINE AND HUMANIZED CONSTRUCTS OF MONOCLONAL ANTIBODY M195 (ANTI-CD33) FOR THE THERAPY OF ACUTE MYELOGENOUS LEUKEMIA", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 73, no. 3, SUPPL, 1 January 1994 (1994-01-01), pages 1049-1056, XP009036638, ISSN: 0008-543X**
- **CARON P C ET AL: "ENGINEERED HUMANIZED DIMERIC FORMS OF IGG ARE MORE EFFECTIVE ANTIBODIES", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 176, no. 4, 1 January 1992 (1992-01-01), pages 1191-1195, XP000914982, ISSN: 0022-1007, DOI: DOI:10.1084/JEM.176.4.1191**
- **KUEGLER MARKUS ET AL: "A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 150, no. 5, 1 September 2010 (2010-09-01), pages 574-586, XP009142424, ISSN: 0007-1048, DOI: DOI:10.1111/J.1365-2141.2010.08300.X[retrieved on 2010-07-16]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 625 201 B1

- SINGER HEIKO ET AL: "Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 33, no. 6, 1 July 2010 (2010-07-01), pages 599-608, XP009142457, ISSN: 1524-9557, DOI: DOI:10.1097/CJI.0B013E3181DDA225
- LINENBERGER MICHAEL L ET AL: "Antibody-directed therapies for hematological malignancies", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, GB, vol. 8, no. 2, 1 February 2002 (2002-02-01), pages 69-76, XP009142419, ISSN: 1471-4914
- KORVER W ET AL: "Monoclonal antibodies against IREM-1: potential for targeted therapy of AML", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 23, no. 9, 1 September 2009 (2009-09-01), pages 1587-1597, XP009142413, ISSN: 0887-6924
- LAZAR GREG A ET AL: "Engineered antibody Fc variants with enhanced effector function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 103, no. 11, 14 March 2006 (2006-03-14), pages 4005-4010, XP002590010, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.0508123103
- CARTER P J: "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 6, 7 April 2006 (2006-04-07), pages 343-357, XP007901440, ISSN: 1474-1733, DOI: DOI:10.1038/NRI1837
- MAN SUNG CO: "CHIMERIC AND HUMANIZED ANTIBODIES WITH SPECIFICITY FOR THE CD33 ANTIGEN1", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 148, no. 4, 15 February 1992 (1992-02-15), pages 1149-1154, XP000368716, ISSN: 0022-1767

Description

Field of the invention

[0001] The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

Background of the invention

[0002] In the early 1980s CD33 was identified as a marker of myeloid leukemias (Andrews et al., Blood 62, 24-132, 1983). CD33 is a cell-surface antigen specifically expressed on myeloid cells including myeloid leukemia cells. It is the smallest member of the siglec (sialic acid-binding Ig-related lectins) family. CD33 is expressed on early multilineage hematopoietic progenitor cells and myelomonocytic precursors. It is absent from pluripotent hematopoietic stem cells (Andrews et al., Journal of Experimental Medicine 169, 1721-1731, 1989). It is downregulated on mature granulocytes but retained on macrophages, monocytes and dendritic cells (Andrews et al., Blood 62, 24-132, 1983). Besides myelomonocytic cells, CD33 has also been found to be expressed on human mast cells and blood basophils (Valent et al., Blood 15; 73(7):1778-85, 1989). Monoclonal antibodies directed against CD33 are used in diagnosis of leukemia as well as for therapeutic targeting and *in vitro* purging of bone marrow for autologous transplantation in acute myeloid leukemia (AML) (Duzkale et al., Biol Blood Marrow Transplant. 9(6):364-72, 2003). Initial efforts in therapeutic targeting focused on the development of immunotoxins using an anti-CD33 antibody conjugated to the toxin ricin. Since CD33 rapidly internalizes upon antibody binding (Audran et al., J Immunol Methods. 188(1): 147-54, 1995) the immunotoxin approach was obvious.

[0003] CD33 is a 67 KD transmembrane glycoprotein. The sialic acid-binding extracellular domain of CD33 is involved in cell-cell adhesion. The intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM) confer inhibitory signals to the cell, affecting proliferation and cell survival. The actual signalling pathways of CD33 are poorly understood but are assumed to involve the ITIM and ITIM-like motifs and the recruitment of tyrosine phosphatases (von Gunten et al., Ann. N.Y. Acad. Sci. 1143: 61-82, 2008). A murine CD33 orthologue has been defined but its functional comparability to human CD33 was questioned (Brinkman-Van der Linden et al., Mol Cell Biol., 23(12): 4199-206, 2003). The functional role of human CD33 on normal and malignant leukocytes remains unknown.

[0004] Several publications have described CD33 as a stable cell surface marker on primary AML and CML cells expressed by 70-100% of tested patients (Plesa et al., Cancer 112(3), 572-80, 2007; Hauswirt et al., Eur J Clin Invest. Jan 73-82, 2007; Scheinberg et al., Leukemia Vol. 3, 440-445, 1989). CD33 is expressed on malignant myeloid blast cells, which represent the majority of malignant cells in peripheral blood and bone marrow of leukemia patients, and on leukemic stem cells, a relatively small number of less differentiated cells in the bone marrow which are characterized by their capacity for self-renewal and the maintenance of the leukemic clonal hierarchy. Depletion of leukemic stem cells is regarded the key mechanism for sustained tumor free survival. The CD33 targeting immunotoxin Mylotarg®, a humanized IgG₄ antibody conjugated to the toxin chaliceamicin is used for the treatment of AML patients by delivering its toxic payload to CD33 positive AML cells (Amadori et al., Cancer Treat Rev. 34(1):49-60, 2008). Lintuzumab (SGN-33, HuM195, see e.g. Caron et al., Cancer Research 52:24, 6761-6767, 1992) a "naked" CD33 specific humanized monoclonal antibody was evaluated in phase II clinical trials for the treatment of AML and MDS with initial clinical signs of efficacy from a phase I dose escalation study and tolerable adverse events being reported (Raza et al. Abstract #983, 14th EHA Congress, June 4-7, 2009).

[0005] Targeting AML cell lines with CD33 specific HuM195 *in vitro* reduces TNF- α induced secretion of inflammatory cytokines like IL-8, MCP-1 and RANTES (Sutherland et al., Mabs 1:5, 481-490, 2009). The relevance of this effect for AML therapy is unknown but modulating the cytokine milieu of the tumor microenvironment may contribute to the therapeutic efficacy of the antibody. In addition, the antibody induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) of AML cell lines *in vitro* (Sutherland et al., Mabs 1:5, 481-490, 2009). ADCC is considered to be a decisive mechanism for anti-tumor activity of antibodies in hematological malignancies. Data from clinical trials with the CD20-specific monoclonal antibody Rituximab have demonstrated the significance of effector cell mediated mechanisms for treatment of B-cell malignancies with respect to response to antibody treatment (Weng and Levy, J Clin Oncol. 21 (21): 3940-7, 2003).

[0006] In conclusion, it has been shown that CD33 antigen is expressed on normal cells of the myelomonocytic lineage and frequently expressed on tumor cells in myeloid leukemias. In a phase I trial with an antibody against CD33 (lintuzumab) first signs of efficacy were observed without severe adverse events. However, clinical development of lintuzumab was discontinued after results from a phase II trial in combination with chemotherapy did not yield the expected improvement in efficacy. Therefore, there is a clear need for the development of improved CD33-targeting treatment modalities.

[0007] In view of the prior art there is a need for providing a further improved therapy for myeloid cell malignancies

and MDS, particularly for acute myeloid leukemia.

[0008] In particular there is a need for providing further improved antagonistic binding agents to CD33 for treating cancer, in particular AML

Summary of the invention

[0009] The present invention provides novel CD33 binding agents binding to human CD33 and that are defined by

- a) having a heavy chain variable region comprising CDR1, CDR2 and CDR3, and a light chain variable region comprising CDR4, CDR5 and CDR6, wherein CDR1 has an amino acid sequence selected from SeqID No: 1-14, CDR2 has an amino acid sequence selected from SeqID No: 14-28, CDR3 has an amino acid sequence selected from SeqID No:29-42, CDR4 has an amino acid sequence selected from SeqID No:43-56, CDR5 has an amino acid sequence selected from SeqID No:57-70, CDR6 has an amino acid sequence selected from SeqID No:71-84, or
- b) recognizing an epitope within the amino acid sequence FFHPIPYDKNSPVHGYW (SeqID No: 141) of human CD33.

[0010] The present invention further provides CD33 binding agents wherein the internalization kinetics of the CD33 binding agents are such that at least 30%, preferably 40%, of the initial amount of the antibody remain on the cell surface of HL60 cells at a time of 4 hours after incubation.

[0011] The present invention further provides CD33 binding agents, wherein the heavy chain variable region comprises an amino acid sequence selected from SeqID No:85-98 and the light chain variable region comprises an amino acid sequence selected from SeqID No:99-112.

[0012] The present invention further provides CD33 binding agents, wherein the heavy chain having an amino acid sequence selected from SeqID No: 113-126 and the light chain having an amino acid sequence selected from SeqID No: 127-140.

[0013] The present invention further provides CD33 binding agents having mutations in the F_c domain that increase ADCC.

[0014] Further preferred embodiments are outlined in the following specification and in the claims.

[0015] The CD33 binding agents according to the present invention have been found to have high affinity to human CD33 and further to have favourable internalization kinetics, which is characterized by a long presence of the CD33 binding agents when bound to CD33 on the surface of the target cells, which translates into favourable ADCC activity.

[0016] The inventors have also found that the CD33 binding agents according to the present invention bind to a different epitope of the extracellular domain of CD33 compared to Lintuzumab. Without wishing to be bound by any particular theory this is believed to be the reason for the different internalization kinetics of the CD33 binding agents according to the present invention and Lintuzumab.

Description of the Figures

[0017]

Figures 1-3 show the internalization of exemplary CD33 binding agents according to the invention in comparison to lintuzumab on HL60 cells.

Figure 4 shows the internalization rate on HL60 cells of two exemplary antibodies according to the invention in comparison to lintuzumab.

Figure 5 shows the ADCC performance on HL60 cells of two exemplary antibodies according to the invention in comparison to lintuzumab.

Detailed description of the invention

CD33 Binding Agents

[0018] The term "binding agent" as used herein means a protein or peptide that specifically binds to a target antigen. A binding agent can be, for example, an antibody, a derivative of such an antibody, or other agent that specifically binds to the target antigen. A binding agent can also be a protein comprising an Fv region or a portion thereof (e.g., a V_H or V_L or a CDR(s) of an antibody that specifically binds to the target antigen). In a preferred embodiment herein the binding agent is an antibody.

[0019] The term "CD33 binding agent" as used herein refers to a binding agent that specifically binds to CD33, typically a portion of the extracellular domain of human CD33.

[0020] The term "antibody" as used herein refers to (a) immunoglobulin polypeptides and immunologically active portions of immunoglobulin polypeptides (i.e., polypeptides of the immunoglobulin family, or fragments thereof, that contain an antigen binding site that immunospecifically binds to a specific target antigen), or (b) conservatively substituted derivatives of such immunoglobulin polypeptides or fragments that immunospecifically bind to the target antigen. Antibodies are generally described in, for example, Harlow and Lane, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 1988). The term "antibody" refers to intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity (e.g., antigen-binding). The antibody can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or sub-class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), preferably of the IgG class, more preferably an IgG1.

[0021] An "intact" antibody is one which comprises an antigen-binding variable region as well as a light chain constant domain and heavy chain constant domains as appropriate for the antibody class. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof.

[0022] An "antibody fragment" comprises a portion of an antibody, including the antigen-binding or variable region or a portion thereof. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments, V_H and V_L antigen binding fragments, diabodies, triabodies, tetrabodies, single-chain antibody, scFv, scFv-Fc, a SMTP, and multispecific antibodies formed from antibody fragment(s).

[0023] "Heavy chain variable region" or "V_H" means the part of the heavy chain comprising the CDR1, CDR2 and CDR3 and surrounding framework regions.

[0024] "Light chain variable region" or "V_L" means the part of the light chain comprising the CDR4, CDR5 and CDR6 and surrounding framework regions.

[0025] "CDR" means the hypervariable regions of the heavy and light chains, which determine the complementarity / binding specificity of an antibody or antibody fragment. The order of the CDRs in the present application is purely numerically.

[0026] "Epitope" herein means a part of an antigen, which is recognized by an antibody or antibody fragment. In particular this term refers to parts of CD33, which can be recognized by an antibody.

[0027] "mAbs" as used herein refers to monoclonal antibodies.

[0028] An antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc.

[0029] "Single-chain Fv" or "scFv" antibody fragments comprise the V_H and V_L domains of an antibody, wherein these domains are present in a single polypeptide chain. The Fv polypeptide typically further comprises a polypeptide linker between the V_H and V_L domains which enables the scFv to form the desired structure for antigen-binding. For a review of scFv, see Plückthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0030] A binding agent such as an antibody that is "directed to," "which binds" or that "specifically binds" an antigen of interest (i.e., a target antigen) is one capable of binding that antigen with sufficient affinity such that the binding agent is useful in targeting a cell expressing the antigen. Typically, the binding agent binds with an affinity of at least about 1x10⁷ M⁻¹, and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

[0031] An "antibody derivative" as used herein refers to an antibody, as defined above, that is modified by covalent attachment of a heterologous molecule such as, e.g., by attachment of a heterologous polypeptide, or by glycosylation, deglycosylation, acetylation or phosphorylation or other modification not normally associated with the antibody. In some embodiments, the heterologous molecule is not a therapeutic agent. In some embodiments, the heterologous molecule does not exhibit a cytostatic or cytotoxic effect by itself.

[0032] A further comprehensive reference for all terms and procedures used herein is Sambrook et al., *Molecular Cloning*, Cold Spring Harbor Laboratory Press; 3rd edition (January 15, 2001).

[0033] The CD33 binding agents specifically bind to a receptor, CD33, associated with a given target cell population. CD33 is a member of the sialoadhesion family that is expressed on cells of the hematopoietic lineage, including myeloid precursors, monocytes, macrophages, dendritic cells, and mast cells. CD33 is also expressed on tumor cells associated with myeloproliferative or mast cell proliferative diseases, including acute myeloid leukemia and myeloplastic syndromes, and on leukemic stem cells. Antibodies targeting CD33 and their uses have been generally described (see, e.g., Pierelli et al., 1993, *Br. J. Haematol.* 84:24-30; Matutes et al., 1985, *Hematol. Oncol.* 3: 179- 186; Taussig et al., 2005, *Blood* 106:4086- 4092; Florian et al., 2006, *Leuk. & Lymph.* 47:207-222).

[0034] In some embodiments, the CD33 binding agent is an antibody (e.g., a monoclonal antibody). Useful monoclonal antibodies can be homogeneous populations of antibodies to a CD33 (e.g., the extracellular domain of human CD33). A monoclonal antibody (mAb) can be prepared by using any technique known in the art. These include, but are not

limited to the hybridoma technique originally described by Köhler and Milstein (1975, Nature 256:495-497), the human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA and IgD and any subclass thereof. The hybridoma producing a

monoclonal antibody may be cultivated *in vitro* or *in vivo*.

[0035] Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies and functionally active antibody fragments of any of these.

[0036] Useful CD33 antibodies include antibodies that can achieve a therapeutic effect by various mechanisms known in the art, such as antibody-dependent cell-mediated cytotoxicity (ADCC), anti-dependent cell phagocytosis (ADCP) and/or complement dependent cytotoxicity (CDC). For example the antibody can mediate ADCC by interacting with immune effector cells such as NK cells, monocytes, and macrophages.

[0037] Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprise both human and non-human portions, which can be made using standard recombinant DNA techniques. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397; both of which are incorporated herein by reference in their entirety). "Humanized antibodies" are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Publication No. WO 87/02671; European Patent Publication No. 0184187; European Patent Publication No. 0171496; European Patent Publication No. 0173494; International Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Publication No. 012023; Berter et al., 1988, Science 240: 1041-1043; Liu et al., 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al., 1987, Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al., 1987, Cancer. Res. 47:999-1005; Wood et al. 1985, Nature 314:446-449; Shaw et al, 1988, J. Natl. Cancer Inst. 80: 1553-1559; Morrison, 1985, Science 229: 1202-1207; Oi et al., 1986, BioTechniques 4:214; U.S. Patent No. 5,225,539; Jones et al., 1986, Nature 321:552-525; Verhoeyan et al., 1988, Science 239:1534; and Beidler et al., 1988, J. Immunol. 141:4053-4060: Human monoclonal antibodies may be made by any of numerous techniques known in the art (see, e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA. 80: 7308-7312; Kozbor et al, 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16; and U.S. Patent Nos. 5,939,598 and 5,770,429).

[0038] Fully human antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a CD33 polypeptide. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see, e.g., Lonberg and Huszar, 1995, Int. Rev. Immunol. 13:65-93. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. Other human antibodies can be obtained commercially from, for example, Medarex (Princeton, NJ), which are obtained by immunizing mice.

[0039] Fully human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection". In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a fully human antibody recognizing the same epitope. (See, e.g., Jespers et al, 1994, Biotechnology 12:899-903). Human antibodies also can be produced using various techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter, 1991, J. Mol. Biol 227:381; Marks et al, 1991, J Mol Biol 222:581 ; Quan and Carter, 2002, The rise of monoclonal antibodies as therapeutics, In Anti-IgE and Allergic Disease, Jardieu and Fick Jr., eds., Marcel Dekker, New York, NY, Chapter 20, pp. 427-469).

[0040] Useful antibody fragments include, but are not limited to, F(ab')₂ fragments, Fab' fragments, Fab fragments, Fvs, single chain antibodies (SCAs) (e.g., as described in U.S. Patent No. 4,946,778: Bird, 1988, Science 242:423-42; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al, 1989, Nature 334: 544-54), scFv, scFv-Fc, FvdsFv, minibodies, diabodies, triabodies, tetrabodies, SMIPs (see, e.g., Published U.S. Patent Application No. 2005-0238646) and any other molecule comprising one or more CDRs and that has the same specificity as the antibody.

[0041] In other embodiments, the antibody is a fusion protein of an antibody, or a functionally active fragment thereof, joined to another protein. For example, an antibody or antibody fragment can be fused via a covalent bond (e.g., a peptide bond), at either the N-terminus or the C-terminus to an amino acid sequence of another protein (or portion thereof, typically at least a 10, 20 or 50 amino acid portion of the protein) that is not the antibody or an antibody fragment. In some embodiments, the antibody or fragment thereof can be covalently linked to the other protein at the C-terminus of the variable domain or a constant domain.

[0042] Antibodies can be modified, e.g., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retain its antigen-binding immunospecificity. For example, a derivative of an antibody can be one that has been further modified, e.g., by glycosylation, de-glycosylation, acetylation, pegylation, phosphorylation, amidation, derealization by known protecting/blocking groups, proteolytic cleavage, linkage to another protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis in the presence of tunicamycin, or the like. Additionally, the derivative can contain one or more unnatural amino acids.

[0043] In specific embodiments, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. (See, e.g., U.S. Patent Publication Nos. 2006-0003412 and 2006-0008882). Amino acid sequence variants of the antibodies are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletions, insertions, and/or substitutions is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the antibody, such as changing the number or position of glycosylation sites.

[0044] A useful method for identification of certain residues or regions of the antibody that are favored locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989, Science 244: 1081-1085). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (typically alanine or polyalanine) to affect the interaction of the amino acids with antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, alanine scanning or random mutagenesis is conducted at the target codon or region and the expressed antibody variants are screened for the desired activity.

[0045] Amino acid sequence insertions can include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide.

[0046] Another type of antibody is an amino acid substitution variant of an antibody. Such variants have at least one amino acid residue in the antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but framework region alterations are also contemplated.

[0047] Substantial modifications in the biological properties of the antibody can be accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally-occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

(4) basic: asn, gin, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic: trp, tyr, phe.

[0048] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

[0049] It is desirable to modify the antibody with respect to effector function, e.g., so as to enhance antibody-dependent cell-mediated cytotoxicity (ADCC), anti-dependent cell phagocytosis (ADCP) and/or complement dependent cytotoxicity (CDC) of the antibody. In particular, the ADCC activity can be enhanced by introducing amino acid mutations in the constant region of the antibody (Lazar et al., PNAS 103, 11, 4005-4010, 2006). This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody, see, e.g., Published U.S. Patent Application No. 2006-0160996. Alternatively or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved inter-

nalization capability and/or increased CDC and ADCC. (See, e.g., Caron et al., 1992, J Exp. Med 176:1191-1195; and Shopes, 1992, J. Immunol. 148:2918-2922.) Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al., 1993, Cancer Research 53:2560-2565. Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. (See, e.g., Stevenson et al., 1989, Anti-Cancer Drug Design 3:219-230.)

[0050] A variety of modifications of the Fc region have been suggested in the art, both in the scientific literature and in patent documents, e.g. in EP 0307434, WO 9304173, WO 9734631, WO 9744362, WO 9805787, WO 9943713, WO 9951642, WO 9958572, WO 02060919, WO 03074679, WO 2004016750, WO 2004029207, WO 2004063351, WO 2004074455, WO 2004035752, WO 2004099249, WO 2005077981, WO 2005092925, WO 2006019447, WO 2006031994, WO 2006047350, WO 2006053301, WO 2006088494 and WO 2007041635.

[0051] In preferred embodiments, the antibodies of the invention are Fc variants with amino acid substitutions at positions 332 and/or 239 and/or 236. In preferred embodiments, the antibodies of the invention have mutations in the Fc domain selected from the group of

- i) a single substitution at position 332, preferably I332E;
- ii) a combination of substitutions at positions 239 and 332, preferably S239D/I332E;
- iii) a combination of substitutions at positions 236 and 332, preferably G236A/I332E;
- iv) a combination of substitutions at positions 236, 239 and, 332, preferably G236A/S239D/I332E.

[0052] In this context it is particularly preferred to introduce mutations in the F_c domain at one or more positions selected from amino acids at positions 332 and/or 239 and/or 236 according to the Kabat EU numbering index. Particular preferred are substitutions at positions 239 and 332, especially S239D/I332E.

[0053] The Fc variants in the antibodies of the present invention are defined according to the amino acid modifications that compose them. Thus, for example, I332E is an Fc variant with the substitution I332E relative to the parent Fc polypeptide. Likewise, S239D/I332E defines an Fc variant with the substitutions S239D and I332E and S239D/I332E/G236A defines an Fc variant with the substitutions S239D, I332E, and G236A relative to the parent Fc polypeptide.

[0054] To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an antibody fragment) as described in U.S. Patent No. 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, or IgG₄) that is responsible for increasing the in vivo serum half-life of the IgG molecule.

[0055] Antibodies may be glycosylated at conserved positions in their constant regions (see, e.g., Jefferis and Lund, 1997, Chem. Immunol. 65:11 1-128; Wright and Morrison, 1997, TibTECH 15:26-32). The oligosaccharide side chains of the immunoglobulins can affect the protein's function (see, e.g., Boyd et al., 1996, Mol. Immunol. 32: 1311 -1318; Wittwe and Howard, 1990, Biochem. 29: 4175-4180), and the intramolecular interaction between portions of the glycoprotein which can affect the conformation and presented three-dimensional surface of the glycoprotein (see, e.g., Jefferis and Lund, supra; Wyss and Wagner, 1996, Current Opin. Biotech. 7:409-416). Oligosaccharides may also serve to target a given glycoprotein to certain molecules based upon specific recognition structures. For example, it has been reported that in a galactosylated IgG, the oligosaccharide moiety 'flips' out of the inter-C_H2 space and terminal N-acetylglucosamine residues become available to bind mannose binding protein (see, e.g., Malhotra et al. 1995, Nature Med. 1 :237-243). Removal by glycopeptidase of the oligosaccharides from CAMPATH-1H (a recombinant humanized murine monoclonal IgG1 antibody which recognizes the CDw52 antigen of human lymphocytes) produced in Chinese Hamster Ovary (CHO) cells resulted in a complete reduction in complement mediated lysis (CMCL or CDC) (Boyd et al., 1996, Mol. Immunol. 32:131, 1-1318), while selective removal of sialic acid residues using neuraminidase resulted in no loss of CMCL. Glycosylation of antibodies has also been reported to affect ADCC. In particular, CHO cells with tetracycline-regulated expression of β (1.4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisecting GlcNAc, was reported to have improved ADCC activity (see, e.g., Umana et al., 1999, Nature Biotech. 17: 176-180).

[0056] Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylglucosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.

[0057] Glycosylation variants of antibodies are variants in which the glycosylation pattern of an antibody is altered. By altering is meant deleting one or more carbohydrate moieties found in the antibody, adding one or more carbohydrate moieties to the antibody, changing the composition of glycosylation (i.e., glycosylation pattern), the extent of glycosylation,

or the like.

[0058] Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). Similarly, removal of glycosylation sites can be accomplished by amino acid alteration within the native glycosylation sites of the antibody.

[0059] The amino acid sequence is usually altered by altering the underlying nucleic acid sequence. These methods include, but are not limited to, isolation from a natural source (in the case of naturally-occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, or cassette mutagenesis of an earlier prepared variant or a non-variant version of the antibody.

[0060] The glycosylation (including glycosylation pattern) of antibodies may also be altered without altering the amino acid sequence or the underlying nucleotide sequence. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for expression of recombinant glycoproteins, e.g., antibodies, as potential therapeutics is rarely the native cell, significant variations in the glycosylation pattern of the antibodies can be expected. (See, e.g., Hse et al., 1997, Biol. Chem. 272:9062-9070.) In addition to the choice of host cells, factors which affect glycosylation during recombinant production of antibodies include growth mode, media formulation, culture density, oxygenation, pH, purification schemes, and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host organism, including introducing or overexpressing certain enzymes involved in oligosaccharide production (see, e.g., U.S. Patent Nos. 5,047,335; 5,510,261; and 5,278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example using endoglycosidase H (Endo H). In addition, the recombinant host cell can be genetically engineered, e.g., made defective in processing certain types of polysaccharides. These and similar techniques are well known in the art.

[0061] The glycosylation structure of antibodies can be readily analyzed by conventional techniques of carbohydrate analysis, including lectin chromatography, NMR, mass spectrometry, HPLC, GPC, monosaccharide compositional analysis, sequential enzymatic digestion, and HPAEC-PAD, which uses high pH anion exchange chromatography to separate oligosaccharides based on charge. Methods for releasing oligosaccharides for analytical purposes are also known, and include, without limitation, enzymatic treatment (commonly performed using peptide-N-glycosidase F/endo- β -galactosidase), elimination using harsh alkaline environment to release mainly O-linked structures, and chemical methods using anhydrous hydrazine to release both N- and O-linked oligosaccharides.

[0062] The antibodies also can have modifications (e.g., substitutions, deletions or additions) in amino acid residues that interact with Fc receptors. In particular, antibodies can have modifications in amino acid residues identified as involved in the interaction between the anti-Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97/34631).

[0063] In its broadest aspect the present invention relates to CD33 binding agents binding to human CD33 and that are defined by

- a) having a heavy chain variable region comprising CDR1, CDR2 and CDR3, and a light chain variable region comprising CDR4, CDR5 and CDR6, wherein CDR1 has an amino acid sequence selected from SeqID No: 1-14, CDR2 has an amino acid sequence selected from SeqID No: 15-28, CDR3 has an amino acid sequence selected from SeqID No:29-42, CDR4 has an amino acid sequence selected from SeqID No:43-56, CDR5 has an amino acid sequence selected from SeqID No:57-70, CDR6 has an amino acid sequence selected from SeqID No:71-84, or
- b) recognizing an epitope within the amino acid sequence FFHPIPYDKNSPVHGYW (SeqID No: 141) of human CD33.

[0064] The present invention further provides CD33 binding agents wherein the internalization kinetics of the CD33 binding agents are such that at least 30% of the initial amount of the antibody remain on the cell surface of HL60 cells at a time of 4 hours after incubation.

[0065] It has been found that the CD33 binding agents according to the present invention bind to a different epitope than lintuzumab, see example 4 herein. Both epitopes (SeqID No: 141 and SeqID No: 142) are non-overlapping. It is believed that the different epitopes on the extracellular domain of CD33, which are recognized by the CD33 binding agents according to the present invention and by lintuzumab, are the reason for the different internalization behaviour and ADCC performance of the CD33 binding agents according to the present invention and lintuzumab (cf. examples 2 and 3 herein).

[0066] In a preferred embodiment at least 40% of the initial amount of the CD33 binding agents remain on the cell surface at a time of 4 hours after incubation.

[0067] In a preferred embodiment the heavy chain variable region comprises an amino acid sequence selected from SeqID No:85-98 and the light chain variable region comprises an amino acid sequence selected from SeqID No:99-112.

[0068] In a preferred embodiment the CD33 binding agent has a heavy chain having an amino acid sequence selected

from SeqID No: 113-126 and a light chain having an amino acid sequence selected from SeqID No: 127-140.

[0069] In a preferred embodiment the CD33 binding agent has an affinity to both human CD33 and cynomolgus CD33 with a K_D of equal to or less than 10 nM.

[0070] In a preferred embodiment the CD33 binding agent is humanized.

5 **[0071]** In a preferred embodiment the CD33 binding agent is fully human.

[0072] In a preferred embodiment the CD33 binding agent further comprises an effector function.

[0073] In a preferred embodiment the effector function is mediated by an F_c domain.

[0074] In a preferred embodiment the CD33 binding agent comprises one or more mutations in the F_c domain that modulate the function of the F_c domain.

10 **[0075]** In a preferred embodiment the modulation of the function of the F_c domain is an increase of ADCC by at least 10%, preferably 50% or 100%.

[0076] Particularly preferred CD33 binding agents according to the present invention are listed in table 1:

15

20

25

30

35

40

45

50

55

Table 1

No	Clone ID#	SeqID CDR1	SeqID CDR2	SeqID CDR3	SeqID CDR4	SeqID CDR5	SeqID CDR6	SeqID V _H	SeqID V _L	SeqID heavy chain	SeqID light chain
1	280-03-08	1	15	29	43	57	71	85	99	113	127
2	280-21-09	2	16	30	44	58	72	86	100	114	128
3	280-29-12	3	17	31	45	59	73	87	101	115	129
4	280-31-01	4	18	32	46	60	74	88	102	116	130
5	280-31-01 (mut)	5	19	33	47	61	75	89	103	117	131
6	280-34-02	6	20	34	48	62	76	90	104	118	132
7	280-50-01	7	21	35	49	63	77	91	105	119	133
8	280-50-01 (mut)	8	22	36	50	64	78	92	106	120	134
9	280-61-07	9	23	37	51	65	79	93	107	121	135
10	283-03-03	10	24	38	52	66	80	94	108	122	136
11	283-05-01	11	25	39	53	67	81	95	109	123	137
12	283-07-03	12	26	40	54	68	82	96	110	124	138
13	283-11-03	13	27	41	55	69	83	97	111	125	139
14	283-14-01	14	28	42	56	70	84	98	112	126	140

Treatment of Cancer

[0077] Several publications have described CD33 as a cell surface marker on primary AML and CML cells which is expressed on malignant cells of 70% to 100% of patients (Scheinberg et al., 1989; Hauswirt et al., 2007; Plesa et al., 2007; Webber et al., 2008). CD33 is expressed on malignant myeloid blast cells, which represent the majority of malignant cells in peripheral blood and bone marrow of leukemia patients, and on leukemic stem cells, a relatively small number of less differentiated cells in the bone marrow which are characterized by their capacity for self-renewal and the maintenance of the leukemic clonal hierarchy. The clinical feasibility of targeting CD33 using antibodies has been demonstrated by Mylotarg® (Gemtuzumab ozogamizin), an antibody-calicheamycin conjugate which was approved for the treatment of relapsed AML patients not eligible for other treatment options. An alternative approach directed towards CD33 is the development of lintuzumab (SGN-33, HuM195), a humanized IgG1 monoclonal antibody which has shown early signs of efficacy in clinical phase I trials (Raza et al., 2009). Taken together, there is a wealth of data, both preclinical and clinical, that underscore the relevance and feasibility of CD33 targeting for the treatment of AML and other CD33-positive malignancies.

[0078] Acute myeloid leukemia (AML) is a malignancy of the myeloid lineage of white blood cells. This hematological neoplasia is a blood and bone marrow disease that, if left untreated, is typically fatal within weeks to months. There is an estimated prevalence of 30000 cases of AML in the US and 47000 in the European Union (10 year prevalence data confirmed by Mattson-Jack, 2010). AML is the most prevalent form of adult acute leukemia (about 90%), comprising about 33% of new leukemia cases. The median age of patients diagnosed with AML is 67 years. AML accounts for about 1.2% of cancer deaths in the United States.

[0079] AML causes non-specific symptoms such as weight loss, fatigue, fever, and night sweats. AML is diagnosed by blood tests, bone marrow examination, and laboratory tests to determine the AML subtype and to determine treatment decisions.

[0080] Therapy for AML is highly depending on the age and performance status of the patient. Patients who can tolerate intensive induction (and subsequent consolidation and maintenance) chemotherapy will be treated intensely with a combination of cytotoxic drugs. These patients have a likelihood of achieving a complete response of approximately 75%. In this patient population the therapeutic goal is a cure. Still, relapse of AML occurs in about half of the patients within one year after achievement of a complete response. Long-term cure rates are in the 30% range.

[0081] However, higher age at diagnosis or existence of co-morbidities does not allow administration of intensive induction therapy leading to a palliative treatment goal. Therefore, remission rates decline significantly in older patients with AML. The median survival of older patients with AML is less than 6 months.

[0082] In one aspect, the CD33 binding agents are useful for treating cancer, such as by delaying progression of a cancer and/or reducing cancer-associated cachexia, or preventing or delaying recurrence of a hematological malignancy (e.g., leukemia), in a mammal, preferably a human patient. The CD33 binding agent can be administered alone or co-administered with another therapeutic agent. In some embodiments, the CD33 binding agent is co-administered with a standard of care chemotherapeutic. The CD33 binding agent can be administered in an unconjugated form (i.e., not conjugated to a cytotoxin) or as a conjugate.

[0083] In this subsection, a "patient" is a human or other mammal who is undergoing treatment for, or has been diagnosed as having, cancer.

[0084] In some embodiments, the CD33 binding agents are useful for delaying progression of a cancer and/or reducing cancer-associated cachexia in a patient by administering to the patient in need thereof an effective dosage of the CD33 binding agent. Without being bound to a particular mechanism, the CD33 binding agent binds to effector or accessory cells of the myeloid or monocytic lineages (e.g., monocytes, macrophages, dendritic cells, and neutrophils), thereby inhibiting or reducing the production of various cytokines, chemokines and growth factors from the effector or accessory cells and/or the tumor cells. These cytokines, chemokines and growth factors, which can promote the growth and proliferation of tumor cells and/or contribute to cancer cachexia, include, but are not limited to, interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), interleukin-8 (IL-8), interferon- γ (IFN- γ), vascular endothelial growth factor (VEGF), leukemia inhibitory factor (LIF), monocyte chemoattractant protein-1 (MCP-1), RANTES, interleukin-10 (IL-10), interleukin-12 (IL-12), matrix metalloproteinase 2 (MMP2), IP-10 and/or macrophage inflammatory protein 1 α (MIP1 α). The CD33 binding agents also can reduce the migration of macrophages to the site of the tumor cells.

[0085] In some embodiments, administration of an effective dosage of a CD33 binding agent to a patient reduces the levels of at least one cytokine, chemokine or growth factor, which cytokine, chemokine or growth factor can promote the growth and proliferation of tumor cells, promote the migration of non-malignant effector cells, such as tumor associated macrophages (TAMS), to the vicinity of the tumor site and/or contribute to cancer cachexia. In specific embodiments, the cytokine, chemokine or growth factor is for example interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), interleukin-8 (IL-8), interferon- γ (IFN- γ), vascular endothelial growth factor (VEGF), leukemia inhibitory factor (LIF), monocyte chemoattractant protein-1 (MCP-1), RANTES, interleukin-10 (IL-10), interleukin-12 (IL-12), matrix metalloproteinase 2 (MMP2), IP-10 and/or macrophage inflammatory protein 1 α (MIP1 α).

[0086] In another embodiment, a method is provided for delaying progression of a cancer by administering to a patient an effective regimen of a CD33 binding agent that can specifically bind to CD33. As a result of administration of the CD33 binding agent, the progression of the cancer is delayed, such as by reducing the growth or proliferation of the tumor cells, decreasing metastasis, reducing the level of at least one cytokine, chemokine or growth factor, reducing non-malignant effector cells in the vicinity of the tumor cells, or the like.

[0087] In another embodiment, a method is provided for reducing the tumor burden in a patient by administering to the patient an effective regimen of a CD33 binding agent that can specifically bind to CD33. As a result of administration of the CD33 binding agent, the tumor burden in the patient is arrested or reduced, such as by reducing the size or mass of the tumor, reducing the level of at least one cytokine, chemokine or growth factor, reducing non-malignant effector cells in the vicinity of the tumor cells, inhibiting the migration of macrophages in the vicinity of the tumor cells, reducing the number of non-malignant effector cells (e.g., TAMS or macrophages) in the tumor, or the like.

[0088] In another embodiment, a method is provided for reducing the tumor burden or delaying progression of a cancer in a patient by administering to the patient an effective regimen of a CD33 binding agent that can specifically bind to CD33. As a result of administration of the CD33 binding agent, the tumor burden in the patient is arrested or reduced, such as by recruiting immune effector cells like NK cells or macrophages or monocytes, which can destroy tumor cells by immune mediated mechanisms.

[0089] Antibody dependent cellular cytotoxicity (ADCC) is an immune effector cell mediated mechanism which may contribute to anti-tumor activity of monoclonal antibodies (Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39(1-3):271-8). The relevance of ADCC for anti-tumor efficacy has been demonstrated in preclinical models, e.g. in mouse tumor models (e.g. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443-6). Data from clinical trials support the relevance of ADCC for clinical efficacy of therapeutic antibodies (e.g. Weng WK, Levy R Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003 Nov 1;21(21):3940-7. Epub 2003 Sep 15). Interactions of monoclonal antibodies with Fc receptors on immune cells contribute to ADCC. The Fc of antibodies can be modified in order to display enhanced affinity to Fc receptors (e.g. Presta LG Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):640-56. Epub 2006 May 23). Such enhanced affinity to Fc receptors results in increased ADCC activity which may lead to increased anti tumor efficacy in patients.

[0090] In the various embodiments described in this section, the CD33 binding agent can be used to treat a CD33 positive cancer (i.e., a cancer comprised of cancer cells that over express CD33 on their cell surface, or that express CD33 at levels considered acceptable for therapy with CD33 antibodies). The CD33 binding agent also can be used to treat a cancer that does not overexpress CD33 on the non-malignant effector cells relative to normal tissue of the same type. The cancer can be, for example, a non-hematological malignancy or a hematological malignancy. In specific examples, the hematological malignancy can be CD33-positive and can be, for example, acute lymphoid leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, an erythrocytic leukemia, acute megakaryoblastic leukemia, histiocytic lymphoma, a myeloid sarcoma, a mast cell proliferative disorder or myelodysplastic syndrome (MDS). In some embodiments, the hematological malignancy is a CD33-positive malignancy, such as acute myeloid leukemia or myelodysplastic syndrome (MDS).

[0091] In the various embodiments described in this section, the CD33 binding agent can be an unconjugated anti-CD33 antibody. For example, the antibody can be a fully human, humanized or chimeric antibody, such as a chimeric or humanized M 195 antibody. The antibody also can be another antibody, such as an antibody that competes with M 195 antibody for specific binding to CD33. The antibody also can bind to the same epitope as M 195 antibody or to a different epitope.

[0092] In other embodiments, the CD33 binding agent can be bound (i.e., conjugated) to a cytotoxin. The cytotoxin can be, for example, a peptide toxin, such as saporin, ricin, chlorotoxin, pseudomonas exotoxin, pseudomonas endotoxin or diphtheria toxin. The cytotoxin also can be a chemical (i.e., non-peptide-based) toxin, such as a calicheamicin, doxorubicin, a camptothecin, daunorubicin, or other DNA binding agents. The cytotoxin also can be an auristatin, a maytansinoid, a dolastatin, or other microtubule blocking agents.

[0093] A CD33 binding agent that is an anti-CD33 antibody can be administered to the patient intravenously or subcutaneously at a dose of 0.1 mg/kg or less to about 25 mg/kg, preferably 1.0 mg/kg to about 10 mg/kg. A CD33 binding agent that is an anti-CD33 antibody fragment or other CD33 binding protein can be administered in a dosage equivalent to a dose of 0.1 mg/kg to about 25 mg/kg. 1.0 mg/kg to about 10 mg/kg of intact antibody. The CD33 binding agent can be administered intravenously or subcutaneously to the patient on a schedule that is, for example, daily, weekly, biweekly, tri-weekly (i.e., every three weeks) or monthly, or a combination thereof, to the patient. The CD33 binding agent can be administered for a period of at least one month, at least two months, at least three months, at least four months, at least five month, at least six months, or more, as needed. In some embodiments, a treatment phase (supra) of the CD33 binding agent is followed by a maintenance phase, in which doses of the CD33 binding agent are administered less frequently than during the treatment phase. For example, maintenance doses can be administered weekly, biweekly,

tri-weekly or monthly, for a period of 1-6 months. The dosages in the maintenance phase can be the same as the dosages in the treatment phase.

Treatment of A Hematological Malignancy in Remission

[0094] In another aspect, methods are provided of preventing or delaying recurrence of a hematological malignancy (e.g., leukemia) in a patient by administering to the patient in remission from the hematological malignancy an effective dosage of a CD33 binding agent, resulting in preventing or delaying recurrence of the underlying hematological malignancy. The CD33 binding agent specifically binds to CD33 on the surface of the hematological malignancy (i.e., leukemic cell) and/or to non-malignant effector cells.

[0095] In this disclosure, a "patient" is typically a human who is undergoing treatment for, or has been diagnosed as having, hematological malignancy. In some embodiments, the hematological malignancy is a CD33-positive hematological malignancy. Hematological malignancies include, but are not limited to, leukemias (e.g., acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia, hairy cell leukemia). Related blood disorders include, but are not limited to, myelodysplastic syndrome (MDS), myelofibrosis, myeloproliferative disease (e.g., polycythemia vera (PV, PCV or PRV), essential thrombocythosis (ET)), and amyloid due to light-chain disease.

[0096] The term "CD33-positive hematological malignancy" refers to a hematological malignancy characterized by the expression of CD33 on the surface of the malignant cells. CD33-positive hematological malignancies include, but are not limited to, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, thrombocyte leukemia, a myelodysplastic syndrome, a myeloproliferative disorder, refractory anemia, a preleukemia syndrome, a lymphoid leukemia, or an undifferentiated leukemia.

[0097] In some embodiments, the methods include administering to a patient in remission from a CD33 positive hematological malignancy an effective regimen of a CD33 binding agent, whereby the recurrence of the hematological malignancy is prevented or delayed. In some embodiments, the patient lacks detectable cells of the hematological malignancy. As used herein, a "lack of detectable cells" is determined by standard diagnostic or prognostic methods. A patient in remission from AML typically exhibits resolution of abnormal clinical features, return to normal blood counts and normal hematopoiesis in the bone marrow with <5% blast cells, a neutrophil count of >1,000-1,500, a platelet count of >100,000, and disappearance of the leukemic clone. See, e.g., The Merck Manual, Sec. 11, Ch. 138 (17th ed. 1997); Estey, 2001, Cancer 92(5): 1059-1073.

[0098] The CD33 binding agent can be, for example, an antibody that specifically binds to CD33 and the hematological malignancy can be acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, thymoid leukemia, a myelodysplastic syndrome, a myeloproliferative disorder, refractory anemia, a preleukemia syndrome, a lymphoid leukemia, or an undifferentiated leukemia.

[0099] In some embodiments, the patient in remission from the hematological malignancy has not undergone a bone marrow transplant. In other embodiments, the patient in remission from the hematological malignancy has undergone a bone marrow transplant. The bone marrow transplant can be either an autologous or an allogeneic bone marrow transplant.

[0100] The following cancer types are especially suitable to be treated by the antibodies according to the present invention:

[0101] Blood-borne cancers, including, but not limited to: acute lymphoblastic leukemia "ALL", acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia "AML", acute promyelocytic leukemia "APL", acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia "CML", chronic lymphocytic leukemia "CLL", hairy cell leukemia, multiple myeloma.

[0102] Acute and chronic leukemias, which are suitable to be treated by CD33 binding agents include: lymphoblastic, myelogenous, lymphocytic, myelocytic leukemias and thrombocytic leukemia. Further myelodysplasia syndrome, myeloproliferative disorder, refractory anemia, preleukemia syndrome, lymphoid leukemia, or undifferentiated leukemia can be treated by CD33 binding agents.

Combinations with other Active Substances

[0103] Depending on the disorder to be treated, the CD33 binding agents of the invention may be used on its own or in combination with one or more additional therapeutic agents, in particular selected from DNA damaging, DNA demethylating or tubulin binding agents or therapeutically active compounds that inhibit angiogenesis, signal transduction pathways or mitotic checkpoints in cancer cells or have immunomodulatory function (IMiDs).

[0104] The additional therapeutic agent may be administered simultaneously with, optionally as a component of the same pharmaceutical preparation, or before or after administration of the CD33 binding agent.

[0105] In certain embodiments, the additional therapeutic agent may be, without limitation, one or more inhibitors selected from the group of inhibitors of EGFR family, VEGFR family, VEGF, IGF-1R, Insulin receptors, AuroraA, AuroraB, PLK and PI3 kinase, FGFR, PDGFR, Raf, KSP or PDK1.

[0106] Further examples of additional therapeutic agents are inhibitors of CDKs, Akt, Src, Bcr-Abl, cKit, cMet/HGF, Her2, Her3, c-Myc, Flt3, HSP90, hedgehog antagonists, inhibitors of JAK/STAT, Mek, mTor, NFkappaB, the proteasome, Rho, an inhibitor of Wnt signaling or Notch signaling or an ubiquitination pathway inhibitor.

[0107] Further examples of additional therapeutic agents are inhibitors of DNA polymerase, topoisomerase II, multit-
 yrosine kinase inhibitors, CXCR4 antagonists, IL3RA inhibitors, RAR antagonists, KIR inhibitors, immunotherapeutic
 vaccines, TUB inhibitors, Hsp70 inducers, IAP family inhibitors, DNA methyltransferase inhibitors, TNF inhibitors, ErbB1
 receptor tyrosine kinase inhibitors, multikinase inhibitors, JAK2 inhibitors, RR inhibitors, apoptosis inducers, HGPRTase
 inhibitors, histamine H2 receptor antagonists and CD25 receptor agnosists.

[0108] Examples for Aurora inhibitors are, without limitation, PHA-739358, AZD-1152, AT-9283, CYC-116, R-763, VX-667, MLN-8045, PF-3814735, SNS-314, VX-689, GSK-1070916, TTP-607, PHA-680626, MLN-8237, BI847325 and ENMD-2076.

[0109] Examples for PLK inhibitor are GSK-461364, BI2536 and BI6727.

[0110] Examples for raf inhibitors are BAY-73-4506 (also a VEGFR inhibitor), PLX-4032, RAF-265 (also a VEGFR inhibitor), sorafenib (also a VEGFR inhibitor), XL-281, Nevavar (also an inhibitor of the VEGFR) and PLX4032.

[0111] Examples for KSP inhibitors are ispinesib, ARRY-520, AZD-4877, CK-1122697, GSK-246053A, GSK-923295, MK-0731, SB-743921, LY-2523355, and EMD-534085.

[0112] Examples for a src and/or bcr-abl inhibitors are dasatinib, AZD-0530, bosutinib, XL-228 (also an IGF-1R inhib-
 itor), nilotinib (also a PDGFR and cKit inhibitor), imatinib (also a cKit inhibitor), NS-187, KX2-391, AP-24534 (also an
 inhibitor of EGFR, FGFR, Tie2, Flt3), KM-80 and LS-104 (also an inhibitor of Flt3, Jak2).

[0113] An example for a PDK1 inhibitor is AR-12.

[0114] An example for a Rho inhibitor is BA-210.

[0115] Examples for PI3 kinase inhibitors are PX-866, PX-867, BEZ-235 (also an mTor inhibitor), XL-147, and XL-765
 (also an mTor inhibitor), BGT-226, CDC-0941.

[0116] Examples for inhibitors of cMet or HGF are XL-184 (also an inhibitor of VEGFR, cKit, Flt3), PF-2341066, MK-
 2461, XL-880 (also an inhibitor of VEGFR), MGCD-265 (also an inhibitor of VEGFR, Ron, Tie2), SU-11274, PHA-665752,
 AMG-102, AV-299, ARQ-197, MetMab, CGEN-241, BMS-777607, JNJ-38877605, PF-4217903, SGX-126, CEP-17940,
 AMG-458, INCB-028060, and E-7050.

[0117] An example for a c-Myc inhibitor is CX-3543.

[0118] Examples for Flt3 inhibitors are AC-220 (also an inhibitor of cKit and PDGFR), KW-2449, LS-104 (also an
 inhibitor of bcr-abl and Jak2), MC-2002, SB-1317, lestaurtinib (also an inhibitor of VEGFR, PDGFR, PKC), TG-101348
 (also an inhibitor of JAK2), XL-999 (also an inhibitor of cKit, FGFR, PDGFR and VEGFR), sunitinib (also an inhibitor of
 PDGFR, VEGFR and cKit), and tandutinib (also an inhibitor of PDGFR, and cKit).

[0119] Examples for HSP90 inhibitors are, tanespimycin, alvespimycin, IPI-504, STA-9090, MEDI-561, AU-922,
 CNF-2024, and SNX-5422.

[0120] Examples for JAK/STAT inhibitors are CYT-997 (also interacting with tubulin), TG-101348 (also an inhibitor of
 Flt3), and XL-019.

[0121] Examples for Mek inhibitors are ARRY-142886, AS-703026, PD-325901, AZD-8330, ARRY-704, RDEA-119,
 and XL-518.

[0122] Examples for mTor inhibitors are temsirolimus, deforolimus (which also acts as a VEGF inhibitor), everolimus
 (a VEGF inhibitor in addition), XL-765 (also a PI3 kinase inhibitor), and BEZ-235 (also a PI3 kinase inhibitor).

[0123] Examples for Akt inhibitors are perifosine, GSK-690693, RX-0201, and triciribine.

[0124] Examples for cKit inhibitors are masitinib, OSI-930 (also acts as a VEGFR inhibitor), AC-220 (also an inhibitor
 of Flt3 and PDGFR), tandutinib (also an inhibitor of Flt3 and PDGFR), axitinib (also an inhibitor of VEGFR and PDGFR),
 sunitinib (also an inhibitor of Flt3, PDGFR, VEGFR), and XL-820 (also acts as a VEGFR- and PDGFR inhibitor), imatinib
 (also a bcr-abl inhibitor), nilotinib (also an inhibitor of bcr-abl and PDGFR).

[0125] Examples for hedgehog antagonists are IPI-609, CUR-61414, GDC-0449, IPI-926, and XL-139.

[0126] Examples for CDK inhibitors are seliciclib, AT-7519, P-276, ZK-CDK (also inhibiting VEGFR2 and PDGFR),
 PD-332991, R-547, SNS-032, PHA-690509, PHA-848125, and SCH-727965.

[0127] Examples for proteasome inhibitors are bortezomib, carfilzomib, and NPI-0052 (also an inhibitor of NFkappaB).

[0128] Examples for proteasome inhibitors/NFkappaB pathway inhibitors are bortezomib, carfilzomib, NPI-0052, CEP-
 18770, MLN-2238, PR-047, PR-957, AVE-8680, and SPC-839.

[0129] An example for an inhibitor of the ubiquitination pathway is HBX-41108.

[0130] Examples for demethylating agents are 5-azacitidine and decitabine.

[0131] Examples for anti-angiogenic agents are inhibitors of the FGFR, PDGFR and VEGF(R), and thalidomides, such
 agents being selected from, without limitation, bevacizumab, motesanib, CDP-791, SU-14813, telatinib, KRN-951, ZK-

CDK (also an inhibitor of CDK), ABT-869, BMS-690514, RAF-265, IMC-KDR, IMC-18F1, IMiDs, thalidomide, CC-4047, lenalidomide, ENMD-0995, IMC-D11, Ki-23057, brivanib, cediranib, 1B3, CP-868596, IMC-3G3, R-1530 (also an inhibitor of Flt3), sunitinib (also an inhibitor of cKit and Flt3), axitinib (also an inhibitor of cKit), lestaurtinib (also an inhibitor of Flt3 and PKC), vatalanib, tandutinib (also an inhibitor of Flt3 and cKit), pazopanib, PF-337210, aflibercept, E-7080, CHIR-258, sorafenib tosylate (also an inhibitor of Raf), vandetanib, CP-547632, OSI-930, AEE-788 (also an inhibitor of EGFR and Her2), BAY-57-9352 (also an inhibitor of Raf), BAY-73-4506 (also an inhibitor of Raf), XL-880 (also an inhibitor of cMet), XL-647 (also an inhibitor of EGFR and EphB4), XL-820 (also an inhibitor of cKit), nilotinib (also an inhibitor of cKit and bcr-abl), CYT-116, PTC-299, BMS-584622, CEP-11981, dovitinib, CY-2401401, ENMD-2976 and BIBF1120.

[0132] The additional therapeutic agent may also be selected from EGFR inhibitors, it may be a small molecule EGFR inhibitor or an anti-EGFR antibody. Examples for anti-EGFR antibodies, without limitation, are cetuximab, panitumumab, nimotuzumab, zalutumumab; examples for small molecule EGFR inhibitors are gefitinib, erlotinib, vandetanib (also an inhibitor of the VEGFR) and afatinib (also an inhibitor of Her2). Another example for an EGFR modulator is the EGF fusion toxin.

[0133] Further EGFR and/or Her2 inhibitors useful for combination with an CD33 binding agent of the invention are lapatinib, trastuzumab, pertuzumab, XL-647, neratinib, BMS-599626 ARRY-334543, AV-412, mAB-806, BMS-690514, JNJ-26483327, AEE-788 (also an inhibitor of VEGFR), AZD-8931, ARRY-380 ARRY-333786, IMC-11F8, Zemab, TAK-285, AZD-4769, and afatinib (dual inhibitor of Her2 and EGFR).

[0134] DNA polymerase inhibitors useful in the combination with an CD33 binding agent of the invention are Ara-C/cytarabine, Clolar/ clofarabine.

[0135] A DNA methyltransferase inhibitor useful in the combination with an CD33 binding agent of the invention is Vidaza/azacitidine.

[0136] An apoptosis inducer useful in the combination with an CD33 binding agent of the invention is Trisenox/arsenite trioxide.

[0137] Topoisomerase II inhibitors useful in the combination with an CD33 binding agent of the invention are idarubicin, daunorubicin and mitoxantrone.

[0138] A RAR antagonist useful in the combination with an CD33 binding agent of the invention is Vesanoid/tretinoin.

[0139] A HGPRTase inhibitor useful in the combination with an CD33 binding agent of the invention is Mercapto/mercaptopurine.

[0140] A histamine H2 receptor antagonist useful in the combination with an CD33 binding agent of the invention is Ceplene/histamine dihydrochloride.

[0141] A CD25 receptor agonist useful in the combination with an CD33 binding agent of the invention is IL-2.

[0142] The additional drug may also be selected from agents that target the IGF-1R and insulin receptor pathways. Such agents include antibodies that bind to IGF-1R (e.g. CP-751871, AMG-479, IMC-A12, MK-0646, AVE-1642, R-1507, BIIB-022, SCH-717454, rhu Mab IGFR and novel chemical entities that target the kinase domain of the IGF1-R (e.g. OSI-906 or BMS-554417, XL-228, BMS-754807).

[0143] Other agents that may be advantageously combined in a therapy with the CD33 binding agent of the invention are molecules targeting CD20, including CD20 specific antibodies like rituximab, LY-2469298, ocrelizumab, MEDI-552, IMMU-106, GA-101 (= R7159), XmAb-0367, ofatumumab, radiolabeled CD20 antibodies, like tositumumab and ibritumomab tiuxetan or other CD20 directed proteins, like the SMIP Tru015, PRO-131921, FBT-A05, veltuzumab, R-7159.

[0144] CD33 binding agents may be combined with inhibitors of other surface antigens expressed on leukocytes, in particular antibodies or antibody-like molecules, e.g. anti-CD2 (siplizumab), anti-CD4 (zanolimumab), anti-CD19 (MT-103, MDX-1342, SAR-3419, XmAb-5574), anti-CD22 (epratuzumab), anti-CD23 (lumiliximab), anti-CD30 (iratutumumab), anti-CD32B (MGA-321), anti-CD38 (HuMax-CD38), anti-CD40 (SGN40), anti-CD52 (alemtuzumab), anti-CD80 (galiximab).

[0145] Other agents to be combined with CD33 binding agents are immunotoxins like BL-22 (an anti-CD22 immunotoxin), inotuzumab ozogamicin (an anti-CD23 antibody-calicheamicin conjugate), RFT5.dgA (anti-CD25 Ricin toxin A-chain), SGN-35 (an anti-CD30-auristatin E conjugate), and gemtuzumab ozogamicin (an anti-CD33 calicheamicin conjugate), MDX-1411 (anti-CD70 conjugate), or radiolabeled antibodies like ⁹⁰Y-epratuzumab (anti-CD22 radioimmunoconjugate).

[0146] In addition, CD33 binding agents may be combined with immunomodulators, agents, e.g. antibodies, that induce apoptosis or modify signal transduction pathways like the TRAIL receptor modulators mapatumumab (a TRAIL-1 receptor agonist), lexatumumab (a TRAIL-2 receptor agonist), tigatuzumab, Apomab, AMG-951 and AMG-655; an anti-HLA-DR antibody (like 1D09C3), an anti-CD74, an osteoclast differentiation factor ligand inhibitor (like denosumab), a BAFF antagonist (like AMG-623a) or an agonist of a Toll-like receptor (e.g. TLR-4 or TLR-9).

[0147] Other drugs that may be used in combination with the CD33 binding agents of the present invention are selected from, but not limited to hormones, hormonal analogues and antihormonals (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, hydroxyprogesterone caproate, diethylstilbestrol, testosterone).

one propionate, fluoxymesterone/equivalents, octreotide, arzoxifene, pasireotide, vapreotide, adrenocorticosteroids/antagonists, prednisone, dexamethasone, ainogluthethimide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, exemestane, atamestane, formestane), LHRH agonists and antagonists (e.g. goserelin acetate, leuprolide, abarelix, cetrorelix, deslorelin, histrelin, triptorelin), antimetabolites (e.g. antifolates like methotrexate, trimetrexate, pemetrexed, pyrimidine analogues like 5-fluorouracil, fluorodeoxyuridine, capecitabine, decitabine, nelarabine, 5-azacytidine, and gemcitabine, purine and adenosine analogues such as mercaptopurine, thioguanine, azathioprine, cladribine and pentostatin, cytarabine, fludarabine, clofarabine); antitumor antibiotics (e.g. anthracyclines like doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin dactinomycin, plicamycin, splicamycin, actinomycin D, mitoxantrone, mitoxantroneidarubicin, pixantrone, streptozocin, aphidicolin); platinum derivatives (e.g. cisplatin, oxaliplatin, carboplatin, lobaplatin, satraplatin); alkylating agents (e.g. estramustine, semustine, mechlorethamine, melphalan, chlorambucil, busulphan, dacarbazine, cyclophosphamide, ifosfamide, hydroxyurea, temozolomide, nitrosoureas such as carmustine and lomustine, thiotepea); antimitotic agents (e.g. vinca alkaloids like vinblastine, vindesine, vinorelbine, vinflunine and vincristine; and taxanes like paclitaxel, docetaxel and their formulations, larotaxel; simotaxel, and epothilones like ixabepilone, patupilone, ZK-EPO); topoisomerase inhibitors (e.g. epipodophyllotoxins like etoposide and etopophos, teniposide, amsacrine, topotecan, irinotecan, banoxantrone, camptothecin) and miscellaneous chemotherapeutics such as retinoic acid derivatives, amifostine, anagrelide, interferon alpha, interferon beta, interferon gamma, interleukin-2, procarbazine, N-methylhydrazine, mitotane, and porfimer, bexarotene, celecoxib, ethylenimine/methyl-melamine, triethylenemelamine, triethylene thiophosphoramidate, hexamethylmelamine, and enzymes L-asparaginase, L-arginase and metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, RSU 1069, EO9, RB 6145, SR4233, nicotinamide, 5-bromodeoxyuridine, 5-iododeoxyuridine, bromodeoxycytidine, erythrohydroxynonyl-adenine, anthracenedione, GRN-163L (a competitive telomerase template antagonist), SDX-101 (a PPAR agonist), talabostat (a DPP inhibitor), forodesine (a PNP inhibitor), atacicept (a soluble receptor targeting TNF family members BLYS and APRIL), TNF-alpha neutralizing agents (Enbrel, Humira, Remicade), XL-844 (a CHK1/2 inhibitor), VNP-40101M (a DNA alkylating agent), SPC-2996 (an antisense bcl2 inhibitor), obatoclax (a bcl2 inhibitor), enzastaurin (a PKC beta modulator), vorinostat (an HDAC inhibitor), romidepsin (an HDAC inhibitor), AT-101 (a Bcl-2Bcl-xL inhibitor), plitidepsin (a multi-actioned depsipeptide), SL-11047 (a polyamine metabolism modulators).

[0148] The CD33 binding agents of the invention may also be used in combination with other therapies including surgery, stem cell transplantation, radiotherapy, endocrine therapy, biologic response modifiers, hyperthermia and cryotherapy and agents to attenuate any adverse effect (e.g. antiemetics), G-CSF, GM-CSF, photosensitizers such as hematoporphyrin derivatives, Photofrin, benzoporphyrin derivatives, Npe6, tin etioporphyrin, pheoboride-a bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanines.

Pharmaceutical Compositions and Methods of Administration

[0149] The CD33 binding agents can be in any form that allows for the composition to be administered to a patient. For example, the composition can be in the form of a solid or liquid. The preferred mode of application is parenteral, by infusion or injection (intravenous, intramuscular, subcutaneous, intraperitoneal, intradermal), but other modes of application such as by inhalation, transdermal, intranasal, buccal, oral and intra-tumor may also be applicable. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In one aspect, the compositions are administered parenterally. In yet another aspect, the compounds are administered intravenously.

[0150] Pharmaceutical compositions can be formulated so as to allow a compound to be bioavailable upon administration of the composition to a patient. Compositions can take the form of one or more dosage units, where, for example, a container of a compound in aerosol form can hold a plurality of dosage units.

[0151] Materials used in preparing the pharmaceutical compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of patient (e.g., human), the particular form of the compound, the manner of administration, and the composition employed.

[0152] The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in powder form. The carrier(s) can be liquid, with the compositions being, for example, an injectable liquid. The composition can be in the form of a liquid, e.g., for parenteral injection. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.

[0153] The liquid compositions, whether they are solutions, suspensions or other like form, can also include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or diglycerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; stabilizers such as amino acids; surfactants such as polysorbates; antibacterial agents such as benzyl alcohol or methyl paraben; antioxi-

dants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral composition can be enclosed in ampoule, a disposable syringe or a multiple-dose vial made of glass, plastic or other material. Physiological saline is an exemplary adjuvant. An injectable composition is preferably sterile.

[0154] The CD33 binding agents may also be dried (freeze-dried, spray-dried, spray-freeze dried, dried by near or supercritical gases, vacuum dried, air-dried), precipitated or crystallized or entrapped in microcapsules that are prepared, for example, by coacervation techniques or by interfacial polymerization using, for example, hydroxymethylcellulose or gelatin and poly-(methylmethacrylate), respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), in macroemulsions or precipitated or immobilized onto carriers or surfaces, for example by pcmc technology (protein coated microcrystals). Such techniques are disclosed in Remington: The Science and Practice of Pharmacy, 21st edition, Hendrickson R. Ed.

[0155] The amount of the composition that is effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.

[0156] The compositions comprise an effective amount of a drug(s) or agent(s) such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of a drug or agent by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1% to about 80% by weight of the composition. In one aspect, oral compositions can comprise from about 4% to about 50% of the compound by weight of the composition. In yet another aspect, parent compositions are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the compound.

[0157] For intravenous administration, the composition can comprise from about 1 to about 50 mg of a drug or agent per kg of the patient's body weight. In one aspect, the composition can include from about 1, 1.5 or 2.5 to about 50 mg of a drug or agent per kg of the patient's body weight. In another aspect, the amount administered will be in the range from about 1, 1.5 or 2.5 to about 25 mg/kg of body weight of a drug or agent.

[0158] In some embodiments, the dosage administered to a patient is less than 0.1 mg/kg to about 50 mg/kg of the patient's body weight. (For conversion to mg/mm², a BSA of 1.8 m² and a body weight of 80 kg can be used.)

[0159] As discussed herein, a CD33 binding agent can be administered intravenously or subcutaneously to the patient on a schedule that is, for example, daily, weekly, biweekly, tri-weekly or monthly to the patient. For example, a CD33 binding agent can be administered weekly, for a period of 2 to 10 weeks, typically 3-6 weeks. In some embodiments, the dosage regimen of the CD33 binding agent maintains a blood serum concentration of antibody at least 5 µg/ml or at least 10 µg/ml during the dosage cycle. The CD33 binding agent can be administered, for example, from 1-8, or more cycles. In some embodiments, a CD33 binding agent is administered chronically to a subject.

[0160] By way of example, the invention includes a method of treating a cancer, such as myeloid leukemia, by administering 0.1 mg/kg to 50 mg/kg, for instance about 1.5-8 or 2.5-8 mg/kg, of an anti-CD33 antibody according to the invention weekly. This treatment can be usually be continued for about 1-3 months, typically about two months. In an embodiment, the dosing schedule is maintained until a reduction in blasts is noted. For example, dosing can be continued up to about 6 months. This treatment can be followed by a less frequent dosing schedule, involving for instance biweekly doses (or twice per month). This dosing schedule can be maintained 1, 2, 3, 4, 5, 6 months or more to maintain a reduction in blasts and/or a remission.

[0161] In some embodiments, a prophylactic agent can be administered with a CD33 binding agent to minimize infusion reactions. Suitable prophylactic agents include, for example, methyl prednisolone, diphenhydramine, acetaminophen or other suitable agent. The prophylactic agent can be administered prior to or at about the same time as the CD33 binding agent.

[0162] The drug(s) or agent(s) or compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.). Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer a compound. In certain embodiments, more than one drug or agent or composition is administered to a patient.

[0163] It can be desirable to administer one or more drugs or agents or compositions locally to the area in need of treatment, as appropriate for the drug or agent. This can be achieved, for example, and not by way of limitation, by local infusion during surgery; topical application, e.g., in conjunction with a wound dressing after surgery; by injection: by means of a catheter; by means of a suppository; or by means of an implant, the implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a cancer, tumor or neoplastic or pre-neoplastic tissue.

[0164] The drug(s) or agent(s) or compositions can be delivered in a controlled release system, such as a pump or various polymeric materials. In yet another embodiment, a controlled-release system can be placed in proximity of the

target of the drug(s) or agent(s) or compositions, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, vol. 2, pp. 115-138, 1984). Other controlled-release systems discussed in the review by Langer (1990, *Science* 249: 1527-1533) can be used.

[0165] The drugs or agents are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to animals, particularly human beings, as appropriate for the drug or agent. Typically, the carriers or vehicles for intravenous administration are sterile isotonic aqueous buffer solutions. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally comprise a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where drug or agent is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the drug or agent is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

[0166] Compositions of therapeutic agents also can be administered according to accepted dosage forms in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions can contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered drugs or agents. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used.

[0167] The composition can include various materials that modify the physical form of a solid or liquid dosage unit. For example, the composition can include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and can be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients can be encased in a gelatin capsule.

[0168] The compositions can be administered to a patient in need thereof at a frequency, or over a period of time, that is determined by the attending physician. The compositions can be administered over a period of 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 21 days, 28 days, one month, two months, or longer periods of time. It is understood that the compositions can be administered for any period of time between 1 day and two months or longer.

Production of Antibodies

[0169] Antibodies can be produced using any method useful for the synthesis of antibodies, in particular, such as by recombinant expression or chemical synthesis.

[0170] Recombinant expression of antibodies, or fragments or derivatives thereof, typically involves construction of a nucleic acid that encodes the antibody. If the nucleotide sequence of the antibody is known, a nucleic acid encoding the antibody or a polypeptide thereof may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, *BioTechniques* 17: 242), which involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides, e.g., by PCR.

[0171] Alternatively, a nucleic acid molecule encoding an antibody or a polypeptide thereof can be generated from a suitable source. If a clone containing the nucleic acid encoding the particular antibody is not available, but the sequence of the antibody is known, a nucleic acid encoding the antibody can be obtained from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin) by, e.g., PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.

[0172] If an antibody that specifically recognizes a particular antigen is not commercially available (or a source for a cDNA library for cloning a nucleic acid encoding such an immunoglobulin is not available), antibodies specific for a particular antigen can be generated by any method known in the art, for example, by immunizing a patient, or suitable animal model such as a rabbit or mouse, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, *Nature* 256:495-497) or, as described by Kozbor et al. (1983, *Immunology Today* 4:72) or Cole et al. (1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Alternatively, a clone encoding at least the Fab portion of the antibody can be obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, *Science* 246, 1275-1281) for clones of Fab fragments that

bind the specific antigen or by screening antibody libraries (see, e.g., Clackson et al, 1991, Nature 352:624; Hane et al, 1997, Proc. Natl. Acad. Sci. USA 94:4937).

[0173] Once a nucleic acid sequence encoding at least the variable domain of the antibody is obtained, it can be introduced into a vector containing the nucleotide sequence encoding the constant regions of the antibody (see, e.g., International Publication No. WO 86/05807; WO 89/01036; and U.S. Patent No. 5,122,464). Vectors containing the complete light or heavy chain that allow for the expression of a complete antibody molecule are available. Then, the nucleic acid encoding the antibody can be used to introduce the nucleotide substitution(s) or deletion(s) necessary to substitute (or delete) the one or more variable region cysteine residues participating in an intrachain disulfide bond with an amino acid residue that does not contain a sulfhydryl group. Such modifications can be carried out by any method known in the art for the introduction of specific mutations or deletions in a nucleotide sequence, for example, but not limited to, chemical mutagenesis and in vitro site directed mutagenesis (see, e.g., Hutchinson et al, 1978, J. Biol. Chem. 253:6551).

[0174] In addition, techniques have been developed for the production of "chimeric antibodies" (see, e.g., Morrison et al., 1984, Proc. Natl. Acad. Sci. USA 81: 851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454). A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region, e.g., humanized antibodies.

[0175] Once a nucleic acid sequence encoding an antibody has been obtained, the vector for the production of the antibody can be produced by recombinant DNA technology using techniques known in the art. Methods that are known to those skilled in the art can be used to construct expression vectors containing the antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook et al (1990, Molecular Cloning, A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; and Sambrook et al., 2001; Molecular Cloning, A Laboratory Manual, 3rd Ed., Cold Spring Harbor Publish., Cold Spring Harbor, N.Y.) and Ausubel et al. (eds., 1993-2006, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.).

[0176] An expression vector comprising the nucleotide sequence of an antibody or the nucleotide sequence of an antibody can be transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, calcium phosphate precipitation or transduction), and the resulting cells are then cultured by conventional techniques to produce the antibody. In specific embodiments, the expression of the antibody is regulated by a constitutive, an inducible or a tissue-specific promoter.

[0177] The host cells used to express the recombinant antibody can be either bacterial cells such as *Escherichia coli*, or, preferably, eukaryotic cells, especially for the expression of recombinant immunoglobulin molecules. In particular, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector containing the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for immunoglobulins (see, e.g., Foecking et al., 1986, Gene 45:101; Cockett et al., 1990, BioTechnology 8:2). The CHO cell line can be, for example, DG44 or CHO-S. In another example, an antibody can be expressed using the CHEF system. (See, e.g., U.S. Patent No. 5,888,809.)

[0178] A variety of other host-expression vector systems can be utilized to express antibodies. Such host-expression systems represent vehicles by which the coding sequences of the antibody can be produced and subsequently purified, but also represent cells that can, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody immunoglobulin molecule in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing immunoglobulin coding sequences; yeast (e.g., *Saccharomyces pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the immunoglobulin coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, CHO-S, BH, 293, 293T or 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0179] In bacterial systems, a number of expression vectors can be advantageously selected depending upon the use intended for the antibody being expressed. For example, when a large quantity of such a protein is to be produced, vectors that direct the expression of high levels of fusion protein products that are readily purified might be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al, 1983, EMBO J. 2:1791-94), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke and Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors can also be used to express

foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0180] In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) or the analogous virus from *Drosophila melanogaster* can be used as a vector to express foreign genes. The virus grows in *Spodopiera frugipenta* cells. The antibody coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

[0181] In mammalian host cells, a number of viral-based expression systems can be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) results in a recombinant virus that is viable and capable of expressing the immunoglobulin molecule in infected hosts. (See, e.g., Logan and Shenk, 1984, *Proc. Natl. Acad. Sci. USA* 81:355-359). Specific initiation signals can also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon is operably related to the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner et al., 1987, *Methods in Enzymol.* 153:51-544).

[0182] In addition, a host cell strain can be chosen to modulate the expression of the inserted sequences, or modify and process the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such mammalian host cells include, but are not limited to, CHO (e.g., DG44 or CHO-S), VERY, BH, HeLa, COS, MDCK, 293, 293T, 3T3, WI38, BT483, Hs578T, HTB2, BT20 and T47D, CRL7030 and Hs578Bst.

[0183] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines that stably express an antibody can be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells can be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express the antibody. Such engineered cell lines can be particularly useful in screening and evaluation of tumor antigens that interact directly or indirectly with the antibody.

[0184] A number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (see, e.g., Wigler et al., 1977, *Cell* 11:223), hypoxanthine-guanine phosphoribosyltransferase (see, e.g., Szybalska and Szybalski, 1992, *Proc. Natl. Acad. Sci. USA* 48:202), and adenine phosphoribosyltransferase (see, e.g., Lowy et al., 1980, *Cell* 22:817) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: DHFR, which confers resistance to methotrexate (see e.g., Wigler et al., 1980, *Proc. Natl. Acad. Sci. USA* 77:3567-70; O'Hare et al., 1981, *Proc. Natl. Acad. Sci. USA* 78: 1527-31); gpt, which confers resistance to mycophenolic acid (see, e.g., Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-76); neo, which confers resistance to the aminoglycoside G-418 (see, e.g., *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Arm. Rev. Pharmacol. Toxicol.* 32:573-596; Mulligan, 1993, *Science* 260:926-932; Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62: 191-217; and May, 1993, *TIB TECH* 11(5): 155-215) and hyg^r, which confers resistance to hygromycin (see, e.g., Santerre et al., 1984, *Gene* 30:147-50). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds., 1993-2006, *Current Protocols in Molecular Biology*. John Wiley & Sons, NY; Kriegler, 1990, *Gene Transfer and Expression. A laboratory Manual*, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds., 1994, *Current Protocols in Human Genetics*, John Wiley & Sons, NY; and Colberre-Garapin et al, 1981, *J. Mol. Biol.* 150:1-14).

[0185] The expression levels of an antibody can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol. 3., Academic Press, New York, 1987). When a marker in the vector system expressing an antibody is amplifiable, an increase in the level of inhibitor present in culture of host cell will increase the number of copies of the

marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (see, e.g., Crouse et al., 1983, Mol. Cell. Biol. 3:257-66).

[0186] The host cell can be co-transfected with two expression vectors, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors can contain the same or different selectable markers that enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector can be used to encode both heavy and light chain polypeptides. In such situations, the light chain is typically placed before the heavy chain to avoid an excess of toxic free heavy chain (see, e.g., Proudfoot, 1986, Nature 322:562-65; Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197-9). The coding sequences for the heavy and light chains can comprise cDNA or genomic DNA.

[0187] Once the antibody has been recombinantly expressed, it can be purified using any suitable method for purification of an antibody, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

[0188] A comprehensive reference for all steps used for making the monoclonal antibodies according to the present invention is Yokoyama et al., "Production of Monoclonal Antibodies", Current Protocols in Immunology, Unit 2.5, 2006.

Examples

Example 1: Affinity to CD33

[0189] The CD33 binding agents have a K_D to both human and cynomolgus CD33 of Affinities of 10 nM or less on the cell line HL60 and HEK293-cynomolgus CD33, respectively.

[0190] Fourteen CD33 binding agents (fully human monoclonal antibodies as listed in table 1 as No. 1-14, respectively) to human and cynomolgus CD33 were determined by FACS Scatchard analysis as described in Brockhoff et al., (Cytometry. 1994 Sep 1;17(1):75-83) on CD33 expressing cells (AML-derived HL60 cell line, recombinant HEK293-cynomolgusCD33 cell line). Briefly, dilutions of a CD33 binding agent were prepared in a 96 well plate starting with 100-400 nM in the first well (80 μ l), followed by 11 dilution steps (1:2, 40 + 40 μ l). 50 μ l of CD33 binding agent dilutions are added to FACS tubes, 150 μ l cells (0.8×10^6 /ml = 1.2×10^5 cells/tube) are added to each FACS tube. Cells were gently mixed and incubated for 1 h on ice. Thereafter 50 μ l FITC conjugated secondary antibody (concentration 15 μ g/ml; mouse mAb anti-human IgG) was added, mixed, and incubated for 30 min. on ice. 4 ml PBS pH 7.2 containing 0.02% acid were added thereafter, cells were pelleted and resuspended in 300 μ l PBS pH 7.2 and subjected to FACS analysis using a BD FACS Canto. All experimental steps were performed on wet ice, all CD33 binding agent dilutions were made in PBS/ 0.5% BSA + 0.02% acid. FACS calibration was performed using Quantum FITC MESF (Premix) Beads (Bangs Laboratories). All samples were measured using the same FACS parameters. The ratio of bound IgG versus free IgG was calculated from MFI values at different CD33 binding agent concentrations and displayed as Scatchard blot. A regression line was drawn through the resulting data points, the slope of this line corresponds to the negative value of the association constant. The results are listed in table 2.

Table 2

No	Clone ID #	Human CD33 K_D (nM)	Cynomolgus CD33 K_D (nM)
1	280-03-08	0.3	0.03
2	280-21-09	0.4	0.3
3	280-29-12	0.5	0.6
4	280-31-01	0.4	0.3
5	280-31-01(mut)	1	0.5
6	280-34-02	0.3	0.5
7	280-50-01	0.3	0.5
8	280-50-01(mut)	0.4	1.7
9	280-61-07	0.3	0.4
10	283-03-03	0.3	1.9
11	283-05-01	0.2	1.1
12	283-07-03	0.3	2.1

(continued)

No	Clone ID #	Human CD33 K _D (nM)	Cynomolgus CD33 K _D (nM)
13	283-11-03	0.3	0.6
14	283-14-01	3.2	2.3

Example 2: Internalization kinetics

[0191] Internalization of antibody refers to the reduction of the amount of antibody/ antigen complexes on the cell surface of the target cell after incubation with antibody. Internalization tests were performed with the CD33 expressing HL60 cell line. Cells were incubated with a fixed amount of a CD33 binding agent (10 µg/ml of fully human monoclonal antibodies as listed in table 1 as No. 1-14) for defined time periods (0h, 1h, 4h, 24h) at 37° C to allow internalization of the antibody/antigen complex. At the indicated time points acid was added to the incubation mix to prevent further internalization. Thereafter a fixed amount of CD33 binding agent was added to saturate all CD33 antigen sites on the cell surface. The total amount of CD33 binding agent bound to the cell surface was determined by FACS analysis utilizing a FITC conjugated anti-human IgG secondary antibody. The time point 0h was used to determine the initial level of CD33 antibody/antigen complexes on the surface and was defined as 100%. The results are listed in table 3 and illustrated in Figures 1-3.

Table 3

No	Clone ID #	Remaining CD33 antibody/antigen complexes on the cells surface after 4h incubation with antibody (%)
1	280-03-08	49
2	280-21-09	41
3	280-29-12	49
4	280-31-01	44
5	280-31-01(mut)	52
6	280-34-02	44
7	280-50-01	53
8	280-50-01(mut)	55
9	280-61-07	47
10	283-03-03	45
11	283-05-01	51
12	283-07-03	48
13	283-11-03	46
14	283-14-01	47

[0192] Lintuzumab was included as a reference antibody. Lintuzumab/CD33 complexes rapidly internalized upon binding of lintuzumab which was in accordance to published data. After a 4h-incubation period only about 20% of the initial amount of CD33/lintuzumab complexes was left on the cell surface. It could be demonstrated that, unexpectedly, internalization of all 14 CD33 binding agents according to the present invention was decelerated compared to lintuzumab.

Example 3: ADCC activity

[0193] Decelerated internalization rate translates into increased ADCC activity *in vitro*. To assess the effect of decelerated internalization on the ADCC activity of the CD33 binding agents (fully human monoclonal antibodies as listed in table 1 as No. 1-14), target cells (HL60) were incubated with a CD33 binding agent for the 0, 1, 4 and 24h. Subsequently an ADCC assay was performed with IL-2 stimulated PBMC as effector cells and antibody coated HL60 cells as target cells. For all experiments a mAb concentration of 30 µg/ml was used. The co-cultivation of effector cells with target cells

in presence of CD33 binding agent was performed in quadruplicates or triplicates in 96-well round-bottom microtiter plates in a final volume of 200 μ l assay medium per well consisting of 10% human serum and 1% BSA in RPMI in 1:1 ratio. First effector cells (freshly isolated PBMC cells in 100 μ l 10% human serum in RPMI per well) were plated, followed by target cells and CD33 binding agent solution (diluted in 50 μ l 1% BSA in RPMI). As a control, effector cells were cultivated in assay medium alone (effector cell control) and target cells were cultivated either in assay medium alone (spontaneous lysis) or in assay medium supplemented with 1% Triton X-100 (maximal lysis). The co-culture was incubated at 37°C in a humid CO₂ incubator for 3 hours. At the end of the incubation cells were removed from the culture medium by centrifugation (200 x g, i.e. 1000 rpm; 10 min) at room temperature. Cell free supernatants (100 μ l/well) are transferred into corresponding wells of a 96-well flat-bottom plate. To determine the LDH activity in these supernatants 100 μ l reaction mixture (freshly mixed 250 μ l catalyst with 11.25 ml dye solution) are added to each well and incubated 30 min at room temperature in the dark. Then the absorbance is measured as described below.

[0194] Cytotoxicity Detection Kit (LDH; Roche 11 644 793 001) was used to measure ADCC activity. The detection of cytotoxicity is based on the measurement of LDH enzyme activity released from plasma membrane-damaged cells. LDH released into the culture supernatants reduces the tetrazolium salt from the kit to formazan. The absorption maximum of formazan dye is measured at 490 nm against a reference wavelength of 650 nm in an ELISA plate reader. To determine the percentage cell mediated cytotoxicity the average absorbance of the quadruplicates or triplicates was calculated and the background was subtracted. These corrected values were substituted into the following equation to calculate ADCC (%): (effector/target cell mix-effector cell control-spontaneous release) divided by (maximal release-spontaneous release)

[0195] ADCC activity at timepoint 0h (no antibody pre-incubation of target cells) was defined as 100% ADCC activity. ADCC activity for various timepoints of antibody pre-incubation was calculated relative to timepoint 0h and displayed as relative cytotoxicity (%).

[0196] Decelerated internalization of the CD33 binding agents compared to lintuzumab resulted in increased ADCC activity compared to lintuzumab. In conclusion, decelerated internalization leads to increased ADCC activity. Internalization for the described CD33 binding agents is inversely correlated to ADCC activity of the CD33 binding agents which is indicative for advantages with respect to clinical activity of such CD33 binding agents. The results are illustrated in Figure 4 for the internalization kinetics in this experiment and in Figure 5 for the ADCC activity.

Example 4: Epitope mapping

[0197] The binding epitope of CD33 binding agents described herein relative to the epitope of lintuzumab was determined by Hydrogen Exchange Mass Spectrometry (HXMS).

[0198] This method determined the susceptibility of the amide backbone hydrogens of CD33 protein to exchange with D₂O. The experiments were conducted with recombinant CD33 protein alone and CD33 protein with added CD33 binding agent / lintuzumab (in the following in this example referred to as "antibody / antibodies"). Regions of the CD33 protein showing significant protection from exchange due to binding of antibody were thus identified. Resolution of the method is determined by the peptides produced by digestion with pepsin, e.g. the resulting amino acid sequence may be larger than the actual epitope of the antibody. These CD33 derived peptides were identified by additional control experiments with unexchanged samples employing standard accurate mass and HPLC MS/MS technologies.

[0199] For the protein + antibody sample, CD33 protein and antibody were incubated for 15 minutes at room temperature. The final molar ratio antibody/CD33 was 2:1. Using a LEAP robot system (exchange plate kept at 25°C, sample/quench plate kept at 4°C), 8 μ l of sample was added to 80 μ l of exchange buffer (10mM NaH₂PO₄ in D₂O, pH=7 or 10mM NaH₂PO₄ in H₂O, pH=7), mixed, and allowed to exchange for various times (15, 60, 120, 240, and 600 seconds) at 25°C. 80 μ l of this solution was then transferred to 80 μ l of quench buffer (1M urea, 0.1M TCEP-HCl) at 4°C and mixed. 90 μ l of this solution was then transferred to 10 μ l of pepsin (4 mg/ml) at 4°C and mixed. After 2 minutes, 60 μ l of this solution was injected onto a Michrom C18 trap cartridge. The cartridge was washed with H₂O + 0.1%TFA for 2 minutes at 100 μ l/min. A valve was then switched and the cartridge eluted onto a Phenomenex Jupiter C5 column, 1.0 x 50mm, 5 μ m, 300A. Mobile Phase A was water/acetonitrile/TFA (99/0.95/0.05) and Mobile Phase B was acetonitrile/water/TFA (95/4.95/0.05). Flow rate was 100 μ l/min. Gradient was: 0 minutes (0%B), 6 minutes (40%B), 7 minutes (40%B), 8 minutes (90%B), 10 minutes (90%B), 11 minutes (0%B). The LEAP system pre-cools the mobile phase to 4°C and also maintains the trap column and analytical column at 4°C. For the MS experiments (used to quantitate exchange with the D₂O buffer), a single scan method from 300-2000 for 14 minutes was used at resolution 60,000. For the MS/MS experiments (used to ID peptides with the H₂O exchange buffer), a method with 7 scans was used for 14 minutes. The first scan was a full range scan from 300-2000 at 30,000 resolution. Subsequent scans were CID scans of the 6 most intense ions from scan #1. Isolation width was 1.5amu, collision energy was 35V, activation time was 30msec. Pepsin peptides were identified using fragmentation data and the program Proteome Discoverer (Thermo). Identified peptides were analyzed using an in-house program which calculates the average mass for exchanged peptides.

[0200] All CD33 binding agents protected the identical peptide fragment with the amino acid sequence FFHPIPYD-

KNSPVHGYW (SeqID No: 141) (Table 4). The sequence of CD33 protected by the CD33 binding agents described herein are different and non-overlapping to the peptide sequence of CD33 protected by binding of Lintuzumab (MDP-NFWLQVQE, SeqID No: 142). In silico modeling using the crystal structure of SIGLEC-5, a SIGLEC family member homologous to CD33, revealed binding epitopes of all antibodies in the proximal domain of the protein, where the binding epitope of Lintuzumab is different to those of the CD33 binding agents described herein. In conclusion, the CD33 binding agents described in this patent application bind to a different epitope than Lintuzumab.

Table 4

No	Clone ID #	CD33 Epitope
1	280-03-08	FFHPIPYDKNSPVHGYW
2	280-21-09	FFHPIPYDKNSPVHGYW
3	280-29-12	FFHPIPYDKNSPVHGYW
4	280-31-01	FFHPIPYDKNSPVHGYW
5	280-31-01 (mut)	FFHPIPYDKNSPVHGYW
6	280-34-02	FFHPIPYDKNSPVHGYW
7	280-50-01	FFHPIPYDKNSPVHGYW
8	280-50-01 (mut)	FFHPIPYDKNSPVHGYW
9	280-61-07	FFHPIPYDKNSPVHGYW
10	283-03-03	FFHPIPYDKNSPVHGYW
11	283-05-01	FFHPIPYDKNSPVHGYW
12	283-07-03	FFHPIPYDKNSPVHGYW
13	283-11-03	FFHPIPYDKNSPVHGYW
14	283-14-01	FFHPIPYDKNSPVHGYW
15	Lintuzumab	MDPNFWLQVQE

SEQUENCE LISTING

[0201]

<110> BOEHRINGER INGELHEIM INTERNATIONAL GMBH

<120> CD33 binding agents

<130> 12-0321-PCT

<160> 142

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial

<220>

<223> CDR

<400> 1

EP 2 625 201 B1

Asn Trp Ala Asp Ala Phe Asp Ile
1 5

5 <210> 2
<211> 8
<212> PRT
<213> Artificial

10 <220>
<223> CDR

<400> 2

15 Asn Trp Ala Asp Ala Phe Asp Ile
1 5

20 <210> 3
<211> 8
<212> PRT
<213> Artificial

<220>
<223> CDR

25 <400> 3

His Trp Leu Asp Ala Phe Asp Ile
1 5

30 <210> 4
<211> 8
<212> PRT
<213> Artificial

35 <220>
<223> CDR

<400> 4

40 Asn Trp Ala Asp Ala Phe Asp Ile
1 5

45 <210> 5
<211> 8
<212> PRT
<213> Artificial

<220>
<223> CDR

50 <400> 5

55 Asn Trp Ala Asp Ala Phe Asp Ile
1 5

<210> 6
<211> 8

EP 2 625 201 B1

	<212> PRT						
	<213> Artificial						
5	<220>						
	<223> CDR						
	<400> 6						
10		Asn	Trp	Ala	Asp	Ala	Phe Asp Ile
		1				5	
	<210> 7						
	<211> 8						
15	<212> PRT						
	<213> Artificial						
	<220>						
	<223> CDR						
20	<400> 7						
		Asn	Trp	Ala	Asp	Ala	Phe Asp Ile
		1				5	
25	<210> 8						
	<211> 8						
	<212> PRT						
	<213> Artificial						
30	<220>						
	<223> CDR						
	<400> 8						
35		Asn	Trp	Ala	Asp	Ala	Phe Asp Ile
		1				5	
	<210> 9						
	<211> 8						
40	<212> PRT						
	<213> Artificial						
	<220>						
	<223> CDR						
45	<400> 9						
		Asn	Trp	Ala	Asp	Ala	Phe Asp Ile
		1				5	
50	<210> 10						
	<211> 10						
	<212> PRT						
	<213> Artificial						
55	<220>						
	<223> CDR						

EP 2 625 201 B1

<400> 10

Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu
1 5 10

5

<210> 11

<211> 10

<212> PRT

<213> Artificial

10

<220>

<223> CDR

<400> 11

15

Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu
1 5 10

<210> 12

20

<211> 10

<212> PRT

<213> Artificial

<220>

25

<223> CDR

<400> 12

Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu
1 5 10

30

<210> 13

<211> 10

<212> PRT

35

<213> Artificial

<220>

<223> CDR

40

<400> 13

Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu
1 5 10

45

<210> 14

<211> 10

<212> PRT

<213> Artificial

50

<220>

<223> CDR

<400> 14

55

Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu
1 5 10

<210> 15

EP 2 625 201 B1

<211> 17
 <212> PRT
 <213> Artificial

5 <220>
 <223> CDR

<400> 15

10 Arg Ile Ile Pro Ile Leu Gly Val Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

15 <210> 16
 <211> 17
 <212> PRT
 <213> Artificial

20 <220>
 <223> CDR

<400> 16

25 Arg Ile Ile Pro Ile Ile Asn Ile Ala Ser Tyr Ala Gln Asn Phe Gln
 1 5 10 15

Gly

30 <210> 17
 <211> 17
 <212> PRT
 <213> Artificial

35 <220>
 <223> CDR

<400> 17

40 Arg Ile Ile Pro Ile Ile Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15

Gly

45 <210> 18
 <211> 17
 <212> PRT
 <213> Artificial

50 <220>
 <223> CDR

<400> 18

EP 2 625 201 B1

Arg Ile Ile Pro Ile Leu Gly Val Ala Asp Tyr Ala Gln Lys Phe Gln
1 5 10 15

5 Gly

<210> 19

<211> 17

<212> PRT

10 <213> Artificial

<220>

<223> CDR

15 <400> 19

Arg Ile Ile Pro Ile Leu Gly Val Ala Asp Tyr Ala Gln Lys Phe Gln
1 5 10 15

20 Gly

<210> 20

<211> 17

25 <212> PRT

<213> Artificial

<220>

<223> CDR

30 <400> 20

Arg Ile Ile Pro Ile Val Gly Ile Val Asn Tyr Ala Glu Lys Phe Gln
1 5 10 15

35 Gly

<210> 21

40 <211> 17

<212> PRT

<213> Artificial

<220>

45 <223> CDR

<400> 21

Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe Gln
1 5 10 15

50 Gly

<210> 22

<211> 17

<212> PRT

<213> Artificial

EP 2 625 201 B1

<220>

<223> CDR

<400> 22

5

Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe Gln
1 5 10 15

10

Gly

<210> 23

<211> 17

<212> PRT

15

<213> Artificial

<220>

<223> CDR

20

<400> 23

Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe Glu
1 5 10 15

25

Gly

<210> 24

<211> 17

30

<212> PRT

<213> Artificial

<220>

<223> CDR

35

<400> 24

Arg Ile Ile Pro Ile Leu Asp Met Ala Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15

40

Gly

<210> 25

45

<211> 17

<212> PRT

<213> Artificial

<220>

50

<223> CDR

<400> 25

Arg Ile Ile Pro Ile Ile Gly Ile Val Asn Tyr Ala Gln Lys Phe Gln
1 5 10 15

55

Gly

EP 2 625 201 B1

<210> 26
 <211> 17
 <212> PRT
 <213> Artificial
 5
 <220>
 <223> CDR
 10
 <400> 26
 Arg Ile Ile Pro Ile Leu Gly Met Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15
 15 Gly
 <210> 27
 <211> 17
 <212> PRT
 20 <213> Artificial
 <220>
 <223> CDR
 25 <400> 27
 Arg Ile Ile Pro Ile Ile Gly Ile Val Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15
 30 Gly
 <210> 28
 <211> 17
 35 <212> PRT
 <213> Artificial
 <220>
 <223> CDR
 40 <400> 28
 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln
 1 5 10 15
 45 Gly
 <210> 29
 <211> 5
 <212> PRT
 <213> Artificial
 50
 <220>
 55 <223> CDR
 <400> 29

EP 2 625 201 B1

Asp Tyr Ala Ile Ser
1 5

5 <210> 30
<211> 5
<212> PRT
<213> Artificial

10 <220>
<223> CDR

<400> 30

15 Ser Tyr Ala Ile Ser
1 5

20 <210> 31
<211> 5
<212> PRT
<213> Artificial

<220>
<223> CDR

25 <400> 31

Ser Tyr Ala Ile Ser
1 5

30 <210> 32
<211> 5
<212> PRT
<213> Artificial

35 <220>
<223> CDR

<400> 32

40 Asp Tyr Ala Ile Ser
1 5

45 <210> 33
<211> 5
<212> PRT
<213> Artificial

<220>
<223> CDR

50 <400> 33

Asp Tyr Ala Ile Ser
1 5

55 <210> 34
<211> 5
<212> PRT

EP 2 625 201 B1

	<213> Artificial	
	<220>	
	<223> CDR	
5		
	<400> 34	
		Ser Tyr Ala Ile Ser
10		1 5
	<210> 35	
	<211> 5	
	<212> PRT	
	<213> Artificial	
15		
	<220>	
	<223> CDR	
	<400> 35	
20		
		Ser Tyr Ala Ile Ser
		1 5
	<210> 36	
25	<211> 5	
	<212> PRT	
	<213> Artificial	
	<220>	
30	<223> CDR	
	<400> 36	
		Ser Tyr Ala Ile Ser
35		1 5
	<210> 37	
	<211> 5	
	<212> PRT	
40	<213> Artificial	
	<220>	
	<223> CDR	
45	<400> 37	
		Ser Tyr Ala Ile Ser
		1 5
50	<210> 38	
	<211> 5	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> CDR	
	<400> 38	

EP 2 625 201 B1

Ser Tyr Ala Ile Ser
1 5

5
<210> 39
<211> 5
<212> PRT
<213> Artificial

10
<220>
<223> CDR

<400> 39

15
Ser Tyr Ala Ile Ser
1 5

20
<210> 40
<211> 5
<212> PRT
<213> Artificial

<220>
<223> CDR

25
<400> 40

Ser Tyr Ala Ile Ser
1 5

30
<210> 41
<211> 5
<212> PRT
<213> Artificial

35
<220>
<223> CDR

<400> 41

40
Ser Tyr Ala Ile Ser
1 5

45
<210> 42
<211> 5
<212> PRT
<213> Artificial

<220>
<223> CDR

50
<400> 42

Ser Tyr Ala Ile Ser
1 5

55
<210> 43
<211> 8
<212> PRT

EP 2 625 201 B1

	<213> Artificial	
	<220>	
	<223> CDR	
5	<400> 43	
		Gln Gln Phe Asn Ser Ser Ile Thr
10		1 5
	<210> 44	
	<211> 8	
	<212> PRT	
15	<213> Artificial	
	<220>	
	<223> CDR	
	<400> 44	
20		Gln Gln Phe Asn Ser Ser Ile Thr
		1 5
	<210> 45	
25	<211> 8	
	<212> PRT	
	<213> Artificial	
	<220>	
30	<223> CDR	
	<400> 45	
		Gln Gln Phe Asn Ser Ser Ile Thr
35		1 5
	<210> 46	
	<211> 8	
	<212> PRT	
40	<213> Artificial	
	<220>	
	<223> CDR	
45	<400> 46	
		Gln Gln Phe Asn Ser Ser Ile Thr
		1 5
50	<210> 47	
	<211> 8	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> CDR	
	<400> 47	

EP 2 625 201 B1

Gln Gln Phe Asp Ser Ser Ile Thr
1 5

5
<210> 48
<211> 8
<212> PRT
<213> Artificial

10
<220>
<223> CDR

<400> 48

Gln Gln Phe Asn Ser Ser Tyr Thr
1 5

15
<210> 49
<211> 8
<212> PRT
20 <213> Artificial

<220>
<223> CDR

25 <400> 49

Gln Gln Phe Asn Ser Ser Ile Thr
1 5

30
<210> 50
<211> 8
<212> PRT
<213> Artificial

35
<220>
<223> CDR

<400> 50

Gln Gln Phe Asp Ser Ser Ile Thr
1 5

40
<210> 51
<211> 8
45 <212> PRT
<213> Artificial

<220>
<223> CDR

50
<400> 51

Gln Gln Phe Asn Ser Ser Ile Thr
1 5

55
<210> 52
<211> 8
<212> PRT

EP 2 625 201 B1

	<213> Artificial	
	<220>	
	<223> CDR	
5	<400> 52	
		Gln Gln Phe Asn Ser Ser Ile Thr
10		1 5
	<210> 53	
	<211> 8	
	<212> PRT	
15	<213> Artificial	
	<220>	
	<223> CDR	
20	<400> 53	
		Gln Gln Phe Asn Ser Ser Ile Thr
		1 5
25	<210> 54	
	<211> 8	
	<212> PRT	
	<213> Artificial	
30	<220>	
	<223> CDR	
	<400> 54	
35		Gln Gln Phe Asn Ser Ser Ile Thr
		1 5
40	<210> 55	
	<211> 8	
	<212> PRT	
	<213> Artificial	
	<220>	
	<223> CDR	
45	<400> 55	
		Gln Gln Phe Asn Ser Ser Ile Thr
		1 5
50	<210> 56	
	<211> 8	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> CDR	
	<400> 56	

EP 2 625 201 B1

Gln Gln Phe Asn Ser Ser Ile Thr
1 5

5
<210> 57
<211> 7
<212> PRT
<213> Artificial

10
<220>
<223> CDR

<400> 57

15
Asp Ala Ser Ser Leu Glu Ser
1 5

20
<210> 58
<211> 7
<212> PRT
<213> Artificial

<220>
<223> CDR

25
<400> 58

Asp Ala Ser Ser Leu Glu Ser
1 5

30
<210> 59
<211> 7
<212> PRT
<213> Artificial

35
<220>
<223> CDR

<400> 59

40
Asp Ala Ser Ser Leu Glu Ser
1 5

45
<210> 60
<211> 7
<212> PRT
<213> Artificial

<220>
<223> CDR

50
<400> 60

Asp Ala Ser Ser Leu Glu Ser
1 5

55
<210> 61
<211> 7
<212> PRT

EP 2 625 201 B1

	<213> Artificial		
	<220>		
	<223> CDR		
5	<400> 61		
		Asp Ala Ser Ser Leu Glu Ser	
10		1 5	
	<210> 62		
	<211> 7		
	<212> PRT		
15	<213> Artificial		
	<220>		
	<223> CDR		
	<400> 62		
20		Asp Ala Ser Arg Leu Glu Ser	
		1 5	
	<210> 63		
25	<211> 7		
	<212> PRT		
	<213> Artificial		
	<220>		
30	<223> CDR		
	<400> 63		
		Ala Ala Ser Ser Leu Glu Ser	
35		1 5	
	<210> 64		
	<211> 7		
	<212> PRT		
40	<213> Artificial		
	<220>		
	<223> CDR		
45	<400> 64		
		Ala Ala Ser Ser Leu Glu Ser	
		1 5	
50	<210> 65		
	<211> 7		
	<212> PRT		
	<213> Artificial		
55	<220>		
	<223> CDR		
	<400> 65		

EP 2 625 201 B1

Ala Ala Ser Ser Leu Glu Ser
1 5

5
<210> 66
<211> 7
<212> PRT
<213> Artificial

10
<220>
<223> CDR

<400> 66

15
Asp Ala Ser Ser Leu Glu Ser
1 5

20
<210> 67
<211> 7
<212> PRT
<213> Artificial

<220>
<223> CDR

25
<400> 67

Asp Ala Ser Ser Leu Glu Ser
1 5

30
<210> 68
<211> 7
<212> PRT
<213> Artificial

35
<220>
<223> CDR

<400> 68

40
Asp Ala Ser Ser Leu Glu Ser
1 5

45
<210> 69
<211> 7
<212> PRT
<213> Artificial

<220>
<223> CDR

50
<400> 69

Asp Ala Ser Ser Leu Glu Ser
1 5

55
<210> 70
<211> 7
<212> PRT

EP 2 625 201 B1

	<213> Artificial	
	<220>	
	<223> CDR	
5	<400> 70	
		Asp Ala Ser Ser Leu Glu Ser
10		1 5
	<210> 71	
	<211> 11	
	<212> PRT	
15	<213> Artificial	
	<220>	
	<223> CDR	
	<400> 71	
20		Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
		1 5 10
	<210> 72	
25	<211> 11	
	<212> PRT	
	<213> Artificial	
	<220>	
30	<223> CDR	
	<400> 72	
		Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
35		1 5 10
	<210> 73	
	<211> 11	
	<212> PRT	
40	<213> Artificial	
	<220>	
	<223> CDR	
45	<400> 73	
		Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
		1 5 10
50	<210> 74	
	<211> 11	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> CDR	
	<400> 74	

EP 2 625 201 B1

Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
1 5 10

5
<210> 75
<211> 11
<212> PRT
<213> Artificial

10
<220>
<223> CDR

<400> 75

15 Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
1 5 10

20
<210> 76
<211> 11
<212> PRT
<213> Artificial

<220>
<223> CDR

25
<400> 76

Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
1 5 10

30
<210> 77
<211> 11
<212> PRT
<213> Artificial

35
<220>
<223> CDR

<400> 77

40 Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
1 5 10

45
<210> 78
<211> 11
<212> PRT
<213> Artificial

<220>
<223> CDR

50
<400> 78

Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
1 5 10

55
<210> 79
<211> 11
<212> PRT

EP 2 625 201 B1

	<213> Artificial	
	<220>	
	<223> CDR	
5	<400> 79	
		Arg Ala Ser Gln Gly Ile Ser Ser Val Leu Ala
10		1 5 10
	<210> 80	
	<211> 11	
	<212> PRT	
	<213> Artificial	
15	<220>	
	<223> CDR	
	<400> 80	
20		Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
		1 5 10
	<210> 81	
25	<211> 11	
	<212> PRT	
	<213> Artificial	
	<220>	
30	<223> CDR	
	<400> 81	
		Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
35		1 5 10
	<210> 82	
	<211> 11	
	<212> PRT	
40	<213> Artificial	
	<220>	
	<223> CDR	
45	<400> 82	
		Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
		1 5 10
50	<210> 83	
	<211> 11	
	<212> PRT	
	<213> Artificial	
55	<220>	
	<223> CDR	
	<400> 83	

EP 2 625 201 B1

Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
1 5 10

5 <210> 84
<211> 11
<212> PRT
<213> Artificial

10 <220>
<223> CDR

<400> 84

15 Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
1 5 10

20 <210> 85
<211> 117
<212> PRT
<213> Artificial

<220>
<223> VH

25 <400> 85

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asp Tyr

20 25 30

35 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

40 Gly Arg Ile Ile Pro Ile Leu Gly Val Ala Asn Tyr Ala Gln Lys Phe
50 55 60

45 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Arg Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

50 Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
100 105 110

55 Val Thr Val Ser Ser
115

<210> 86

EP 2 625 201 B1

<211> 117
<212> PRT
<213> Artificial

5 <220>
<223> VH

<400> 86

10 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
20 25 30

20 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Ile Pro Ile Ile Asn Ile Ala Ser Tyr Ala Gln Asn Phe
50 55 60

25 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr
65 70 75 80

30 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
100 105 110

35 Val Thr Val Ser Ser
115

<210> 87
<211> 117
<212> PRT
<213> Artificial

40 <220>
<223> VH

<400> 87

50

55

EP 2 625 201 B1

1 Gln Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Ser
 5 Ser Val Lys Val Ser Cys Lys Val Ser Gly Asp Thr Phe Ser Ser Tyr
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 15 Gly Arg Ile Ile Pro Ile Ile Gly Ile Ala Asn Tyr Ala Gln Lys Phe
 20 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 25 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 30 Ala Arg His Trp Leu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
 35 Val Thr Val Ser Ser
 40 <210> 88
 <211> 117
 <212> PRT
 <213> Artificial
 45 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asp Tyr
 50
 55

EP 2 625 201 B1

	20	25	30
5	Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met		
	35	40	45
10	Gly Arg Ile Ile Pro Ile Leu Gly Val Ala Asp Tyr Ala Gln Lys Phe		
	50	55	60
15	Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Arg Thr Ala Tyr		
	65	70	75
20	Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys		
	85	90	95
25	Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met		
	100	105	110
30	Val Thr Val Ser Ser		
	115		
35	<210> 89		
	<211> 117		
	<212> PRT		
	<213> Artificial		
40	<220>		
	<223> VH		
45	<400> 89		
50			
55			

EP 2 625 201 B1

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Asp	Tyr
				20					25					30		
10	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
15	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Gly	Val	Ala	Asp	Tyr	Ala	Gln	Lys	Phe
	50						55					60				
20	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Arg	Thr	Ala	Tyr
	65					70					75					80
25	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
30	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met
				100					105					110		

Val Thr Val Ser Ser
115

30 <210> 90
 <211> 117
 <212> PRT
 <213> Artificial

35 <220>
 <223> VH

<400> 90

40

45

50

55

EP 2 625 201 B1

1 Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Gln Lys Pro Gly Ser
 5 5 10 15
 5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
 20 25 30
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 15 Gly Arg Ile Ile Pro Ile Val Gly Ile Val Asn Tyr Ala Glu Lys Phe
 50 55 60
 20 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Met Ser Thr Ala Tyr
 65 70 75 80
 25 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 30 Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
 100 105 110
 Val Thr Val Ser Ser
 115
 35 <210> 91
 <211> 117
 <212> PRT
 <213> Artificial
 40 <220>
 <223> VH
 45 <400> 91
 50
 55 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 Ser Val Lys Val Ala Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr

EP 2 625 201 B1

20

25

30

5

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

10

Gly Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe
50 55 60

15

Gln Gly Arg Val Thr Ile Thr Ala Asp Arg Ser Thr Ser Thr Ala Tyr
65 70 75 80

20

Met Ala Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
100 105 110

Val Thr Val Ser Ser
115

25

<210> 92
<211> 117
<212> PRT
<213> Artificial

30

<220>
<223> VH

35

<400> 92

40

45

50

55

EP 2 625 201 B1

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
5	Ser	Val	Lys	Val	Ala	Cys	Lys	Ala	Ser	Gly	Asp	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
10	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
15	Gly	Arg	Val	Ile	Pro	Ile	Ile	Gly	Ile	Ala	Ser	Tyr	Ala	Gln	Asn	Phe
	50						55					60				
20	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Arg	Ser	Thr	Ser	Thr	Ala	Tyr
	65					70					75					80
25	Met	Ala	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
30	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met
				100					105					110		

Val Thr Val Ser Ser
115

30 <210> 93
 <211> 117
 <212> PRT
 <213> Artificial

35 <220>
 <223> VH

<400> 93

40

45

50

55

EP 2 625 201 B1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 5 Ser Val Lys Val Ala Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
 20 25 30
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 15 Gly Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe
 50 55 60
 20 Glu Gly Arg Val Thr Ile Thr Ala Asp Arg Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 25 Met Ala Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 30 Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
 100 105 110
 Val Thr Val Ser Ser
 115
 35 <210> 94
 <211> 119
 <212> PRT
 <213> Artificial
 40 <220>
 <223> VH
 45 <400> 94
 50
 55 Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 45 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
 50
 55

EP 2 625 201 B1

20

25

30

5

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

10

Gly Arg Ile Ile Pro Ile Leu Asp Met Ala Asn Tyr Ala Gln Lys Phe
50 55 60

15

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Tyr Thr Ala Tyr
65 70 75 80

20

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

25

<210> 95

<211> 119

<212> PRT

<213> Artificial

30

<220>

<223> VH

35

<400> 95

40

45

50

55

EP 2 625 201 B1

	Gln	Val	Glu	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Glu	Asp	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
10	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
15	Gly	Arg	Ile	Ile	Pro	Ile	Ile	Gly	Ile	Val	Asn	Tyr	Ala	Gln	Lys	Phe
	50					55					60					
20	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Tyr	Thr	Ala	Tyr
	65				70					75						80
25	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85				90					95		
30	Ala	Arg	Glu	Gly	Gly	Val	Asp	Trp	Tyr	Phe	Asp	Leu	Trp	Gly	Arg	Gly
				100					105					110		
35																
40																
45																
50																
55																

Thr Leu Val Thr Val Ser Ser
115

30 <210> 96
 <211> 119
 <212> PRT
 <213> Artificial

35 <220>
 <223> VH

<400> 96

EP 2 625 201 B1

Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 5 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
 20 25 30
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Arg Ile Ile Pro Ile Leu Gly Met Ala Asn Tyr Ala Gln Lys Phe
 50 55 60
 15 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Tyr Thr Ala Tyr
 65 70 75 80
 20 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 25 Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
 100 105 110
 Thr Leu Val Thr Val Ser Ser
 115
 30 <210> 97
 <211> 119
 <212> PRT
 <213> Artificial
 35 <220>
 <223> VH
 40 <400> 97
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 45 Ser Met Lys Val Ser Cys Lys Ala Ser Glu Asp Thr Phe Ser Ser Tyr

EP 2 625 201 B1

20

25

30

5

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

10

Gly Arg Ile Ile Pro Ile Ile Gly Ile Val Asn Tyr Ala Gln Lys Phe
50 55 60

15

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Cys Thr Ala Tyr
65 70 75 80

20

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

25

<210> 98
<211> 119
<212> PRT
<213> Artificial

30

<220>
<223> VH

35

<400> 98

40

45

50

55

EP 2 625 201 B1

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
10	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
15	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Gly	Ile	Ala	Asn	Tyr	Ala	Gln	Lys	Phe
	50						55					60				
20	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Tyr	Thr	Ala	Tyr
	65					70					75					80
25	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
30	Ala	Arg	Glu	Gly	Gly	Val	Asp	Trp	Tyr	Phe	Asp	Leu	Trp	Gly	Arg	Gly
				100					105					110		
35																
40																
45																
50																
55																

Thr Leu Val Thr Val Ser Ser
115

30 <210> 99
 <211> 107
 <212> PRT
 <213> Artificial

35 <220>
 <223> VL

<400> 99

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val
				20					25					30		
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
35	<210> 100															
	<211> 107															
	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VL															
40	<400> 100															
45	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
50	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
55	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile

EP 2 625 201 B1

	35	40	45
5	Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60		
10	Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80		
15	Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr 85 90 95		
20	Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105		
25	<210> 101 <211> 107 <212> PRT <213> Artificial <220> <223> VL <400> 101		
30	Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15		
35	Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala 20 25 30		
40	Leu Ala Trp Ser Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45		
45	Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60		
50	Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80		
55	Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr 85 90 95		
	Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105		
	<210> 102 <211> 107 <212> PRT <213> Artificial		

EP 2 625 201 B1

<220>

<223> VL

<400> 102

5

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

10

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Val
20 25 30

15

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

20

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

25

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr
85 90 95

30

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 103

<211> 107

<212> PRT

35

<213> Artificial

<220>

<223> VL

40

<400> 103

45

50

55

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val
				20					25					30		
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asp	Ser	Ser	Ile	Thr
						85					90				95	
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							

<210> 104
 <211> 107
 <212> PRT
 <213> Artificial

<220>
 <223> VL

<400> 104

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Asp	Ala	Ser	Arg	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75				80	
25	Glu	Asp	Phe	Thr	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Tyr	Thr
					85					90					95	
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
	<210> 105															
	<211> 107															
	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VL															
35	<400> 105															
40	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
45	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val
				20					25					30		
50																
55																

EP 2 625 201 B1

	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	
			35					40					45				
5	Tyr	Ala	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	
		50					55					60					
10	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	
	65					70					75					80	
15	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr	
					85					90					95		
20	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg						
				100					105								
	<210>	106															
	<211>	107															
	<212>	PRT															
	<213>	Artificial															
25	<220>																
	<223>	VL															
	<400>	106															
30	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	
	1				5					10					15		
35	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val	
				20					25					30			
40	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	
			35					40					45				
45	Tyr	Ala	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	
		50					55					60					
50	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	
	65					70					75					80	
55	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asp	Ser	Ser	Ile	Thr	
					85					90					95		
	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg						
				100					105								
	<210>	107															
	<211>	107															
	<212>	PRT															
	<213>	Artificial															

EP 2 625 201 B1

<220>

<223> VL

<400> 107

5

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

10

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Val
20 25 30

15

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

20

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

25

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr
85 90 95

30

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 108

<211> 107

<212> PRT

35

<213> Artificial

<220>

<223> VL

40

<400> 108

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

45

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30

50

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Met Ile
35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

55

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

EP 2 625 201 B1

	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
5	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
	<210> 109															
	<211> 107															
10	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VL															
15	<400> 109															
	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
20	1				5					10					15	
	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
25	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile
			35					40					45			
30	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50						55					60				
	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
35	65					70					75					80
	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
40	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
	<210> 110															
45	<211> 107															
	<212> PRT															
	<213> Artificial															
	<220>															
50	<223> VL															
	<400> 110															

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile
10			35					40					45			
	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
15	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
20					85					90					95	
	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
25				100					105							
	<210> 111															
	<211> 107															
	<212> PRT															
	<213> Artificial															
30	<220>															
	<223> VL															
	<400> 111															
35																
40																
45																
50																
55																

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile
			35					40					45			
15	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
35	<210> 112															
	<211> 107															
40	<212> PRT															
	<213> Artificial															
45	<220>															
	<223> VL															
50	<400> 112															
55																

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile
			35					40					45			
15	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50						55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
				100					105							
	<210> 113															
	<211> 447															
	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VH															
35	<400> 113															
40	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
45	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Asp	Tyr
				20					25					30		
50	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
55	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Gly	Val	Ala	Asn	Tyr	Ala	Gln	Lys	Phe
	50						55					60				
	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Arg	Thr	Ala	Tyr
	65					70					75					80

EP 2 625 201 B1

	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
5	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	
				100					105					110			
10	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
			115					120					125				
15	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	
		130					135					140					
20	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	
	145					150					155					160	
25	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
					165					170					175		
30	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
35	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
40	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
45	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
	225					230					235					240	
50	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
55	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
60	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
65	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
70	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
	305					310					315					320	
75	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		

EP 2 625 201 B1

	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
5	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
10	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
15	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		
20	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
25	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				
30	<210> 114																
	<211> 447																
	<212> PRT																
	<213> Artificial																
	<220>																
	<223> VH																
35	<400> 114																
40	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Asp	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
45	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
50	Gly	Arg	Ile	Ile	Pro	Ile	Ile	Asn	Ile	Ala	Ser	Tyr	Ala	Gln	Asn	Phe	
	50						55					60					
	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Asn	Thr	Ala	Tyr	
	65					70					75					80	
55	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		

EP 2 625 201 B1

	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	
				100					105					110			
5	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
			115					120					125				
10	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	
		130					135					140					
15	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	
	145					150					155					160	
20	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
					165					170					175		
25	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
30	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
35	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
40	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
		225				230					235					240	
45	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
50	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
55	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
60	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
65	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
		305				310					315					320	
70	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
75	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			

EP 2 625 201 B1

	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
5	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
10	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
15	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		
20	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
25	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				
	<210> 115																
	<211> 447																
	<212> PRT																
	<213> Artificial																
	<220>																
	<223> VH																
30	<400> 115																
35	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Thr	Glu	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
40	Ser	Val	Lys	Val	Ser	Cys	Lys	Val	Ser	Gly	Asp	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
45	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
50	Gly	Arg	Ile	Ile	Pro	Ile	Ile	Gly	Ile	Ala	Asn	Tyr	Ala	Gln	Lys	Phe	
		50					55					60					
55	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Ser	Thr	Ala	Tyr	
	65					70					75					80	
60	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
65	Ala	Arg	His	Trp	Leu	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	
				100					105					110			

EP 2 625 201 B1

	Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu	115	120	125
5	Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys	130	135	140
10	Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser	145	150	155
	Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser	165	170	175
15	Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser	180	185	190
20	Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn	195	200	205
25	Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His	210	215	220
	Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val	225	230	235
30	Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr	245	250	255
35	Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu	260	265	270
40	Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys	275	280	285
	Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser	290	295	300
45	Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys	305	310	315
50	Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile	325	330	335
	Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro	340	345	350
55	Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu	355	360	365

EP 2 625 201 B1

	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
	370						375					380					
5	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
10	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
					405					410					415		
15	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
20	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				
	<210>	116															
	<211>	447															
	<212>	PRT															
	<213>	Artificial															
25	<220>																
	<223>	VH															
	<400>	116															
30	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
35	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Asp	Tyr	
				20					25					30			
40	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
45	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Gly	Val	Ala	Asp	Tyr	Ala	Gln	Lys	Phe	
		50					55					60					
50	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Arg	Thr	Ala	Tyr	
	65					70					75					80	
55	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	
				100					105					110			
60	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
			115					120					125				

EP 2 625 201 B1

	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	
	130						135					140					
5	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	
	145					150					155					160	
	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
10					165					170					175		
	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
15	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
20		210					215					220					
	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
25		225				230					235					240	
	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
30	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
35			275					280					285				
	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
40	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
	305					310					315					320	
	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
45					325					330					335		
	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
50				340					345					350			
	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
55	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					

EP 2 625 201 B1

	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
5	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
					405					410					415		
10	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
15	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				
20	<210> 117																
	<211> 447																
	<212> PRT																
	<213> Artificial																
25	<220>																
	<223> VH																
	<400> 117																
30	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
35	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Asp	Tyr	
				20					25					30			
40	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
45	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Gly	Val	Ala	Asp	Tyr	Ala	Gln	Lys	Phe	
	50						55					60					
50	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Arg	Thr	Ala	Tyr	
	65					70					75					80	
55	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
60	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	
				100					105					110			
65	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
			115					120					125				
70	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	
	130						135					140					

EP 2 625 201 B1

	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	145	150	155				160
5	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser		165	170				175
10	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser		180	185				190
15	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn		195	200				205
20	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His		210	215				220
25	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val		225	230				235
30	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr		245	250				255
35	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu		260	265				270
40	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys		275	280				285
45	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser		290	295				300
50	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys		305	310				315
55	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile		325	330				335
60	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro		340	345				350
65	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu		355	360				365
70	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn		370	375				380
75	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser		385	390				395

EP 2 625 201 B1

	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg
					405					410					415	
5	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu
				420					425					430		
10	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	
			435					440					445			
	<210> 118															
	<211> 447															
	<212> PRT															
15	<213> Artificial															
	<220>															
	<223> VH															
20	<400> 118															
	Gln	Val	Glu	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Gln	Lys	Pro	Gly	Ser
	1				5					10					15	
25	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Asp	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
30	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
35	Gly	Arg	Ile	Ile	Pro	Ile	Val	Gly	Ile	Val	Asn	Tyr	Ala	Glu	Lys	Phe
		50					55					60				
	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Met	Ser	Thr	Ala	Tyr
	65					70					75					80
40	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
45	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met
				100					105					110		
50	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu
			115						120					125		
	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys
		130					135					140				
55	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser
	145					150					155					160

EP 2 625 201 B1

	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
					165					170					175		
5	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
10	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
15	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
20	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
		225				230					235					240	
25	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
30	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
35	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
40	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
45	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
		305				310					315					320	
50	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
55	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
60	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
65	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
70	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
		385				390					395					400	
75	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		

EP 2 625 201 B1

	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu
				420					425					430		
5	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	
		435						440					445			
	<210> 119															
	<211> 447															
10	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VH															
15	<400> 119															
20	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
	Ser	Val	Lys	Val	Ala	Cys	Lys	Ala	Ser	Gly	Asp	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
25																
	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
30																
	Gly	Arg	Val	Ile	Pro	Ile	Ile	Gly	Ile	Ala	Ser	Tyr	Ala	Gln	Asn	Phe
		50					55					60				
35																
	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Arg	Ser	Thr	Ser	Thr	Ala	Tyr
	65					70					75					80
40																
	Met	Ala	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85					90					95	
45																
	Ala	Arg	Asn	Trp	Ala	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met
				100					105					110		
50																
	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu
			115					120					125			
55																
	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys
		130					135					140				
60																
	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser
	145					150					155					160
65																
	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser
					165					170					175	

EP 2 625 201 B1

	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
5	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
10	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
15	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
	225					230					235					240	
20	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
				245					250						255		
25	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
30	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
35	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
40	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
	305					310					315					320	
45	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
50	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
55	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
60	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
65	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
70	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		
75	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			

EP 2 625 201 B1

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 120

<211> 447

<212> PRT

<213> Artificial

<220>

<223> VH

<400> 120

15	Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser	1 5 10 15
20	Ser Val Lys Val Ala Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr	20 25 30
25	Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met	35 40 45
30	Gly Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe	50 55 60
35	Gln Gly Arg Val Thr Ile Thr Ala Asp Arg Ser Thr Ser Thr Ala Tyr	65 70 75 80
40	Met Ala Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys	85 90 95
45	Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met	100 105 110
50	Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu	115 120 125
55	Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys	130 135 140
	Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser	145 150 155 160
	Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser	165 170 175
	Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser	180 185 190

EP 2 625 201 B1

	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
5	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
10	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
		225				230					235					240	
15	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
				245						250					255		
20	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
25	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
30	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
35	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
		305				310					315					320	
40	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
45	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
50	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
55	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
60	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
		385				390					395					400	
65	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		
70	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
75	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				

EP 2 625 201 B1

<210> 121
<211> 447
<212> PRT
<213> Artificial

5

<220>
<223> VH

10

<400> 121

15

20

25

30

35

40

45

50

55

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ala Cys Lys Ala Ser Gly Asp Thr Phe Ser Ser Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Arg Val Ile Pro Ile Ile Gly Ile Ala Ser Tyr Ala Gln Asn Phe
50 55 60

Glu Gly Arg Val Thr Ile Thr Ala Asp Arg Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Ala Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asn Trp Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
100 105 110

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205

EP 2 625 201 B1

	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
	210						215					220					
5	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
	225					230					235					240	
10	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
15	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
20	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
25	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
	290						295					300					
30	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
	305					310					315					320	
35	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
40	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
45	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
50	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
	370						375					380					
55	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
60	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	
				405						410					415		
65	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	
				420					425					430			
70	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
			435					440					445				

<210> 122

<211> 449

<212> PRT
<213> Artificial

5 <220>
 <223> VH

<400> 122

10

15

20

25

30

35

40

45

50

55

EP 2 625 201 B1

	Gln	Val	Glu	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
10	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
15	Gly	Arg	Ile	Ile	Pro	Ile	Leu	Asp	Met	Ala	Asn	Tyr	Ala	Gln	Lys	Phe	
	50						55					60					
20	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Lys	Ser	Thr	Tyr	Thr	Ala	Tyr	
	65					70					75					80	
25	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
30	Ala	Arg	Glu	Gly	Gly	Val	Asp	Trp	Tyr	Phe	Asp	Leu	Trp	Gly	Arg	Gly	
				100					105					110			
35	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	
			115					120					125				
40	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	
		130					135					140					
45	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	
	145					150					155					160	
50	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	
					165					170					175		
55	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	
				180					185					190			
60	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	
			195					200					205				
65	Ser	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	
		210					215					220					

EP 2 625 201 B1

	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225						230				235					240	
5	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
10	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
15	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
20	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
	290						295					300					
25	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
30	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
35	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
40	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
45	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
	370						375					380					
50	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
	385					390					395					400	
55	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
					405					410					415		
60	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
65	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
70	Lys																

<210> 123
 <211> 449
 <212> PRT

EP 2 625 201 B1

<213> Artificial

<220>

<223> VH

5

<400> 123

10

Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Glu Asp Thr Phe Ser Ser Tyr
20 25 30

20

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25

Gly Arg Ile Ile Pro Ile Ile Gly Ile Val Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Tyr Thr Ala Tyr
65 70 75 80

30

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

35

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

40

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

45

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

50

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205

55

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220

EP 2 625 201 B1

	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225						230				235					240	
5	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
10	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
15	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
20	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
	290						295					300					
25	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
30	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
35	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
40	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
45	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
	370						375					380					
50	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
	385					390					395					400	
55	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
					405					410					415		
60	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
65	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
70	Lys																

<210> 124
 <211> 449
 <212> PRT

EP 2 625 201 B1

<213> Artificial

<220>

<223> VH

5

<400> 124

10

Gln Val Glu Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

20

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25

Gly Arg Ile Ile Pro Ile Leu Gly Met Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Tyr Thr Ala Tyr
65 70 75 80

30

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

35

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

40

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

45

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

50

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

55

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220

EP 2 625 201 B1

	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225						230				235					240	
5	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
10	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
15	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
20	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
	290						295					300					
25	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
30	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
35	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
40	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
45	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
	370						375					380					
50	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
	385					390					395					400	
55	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
					405					410					415		
60	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
65	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
70	Lys																

<210> 125
 <211> 449
 <212> PRT

EP 2 625 201 B1

<213> Artificial

<220>

<223> VH

5

<400> 125

10

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Met Lys Val Ser Cys Lys Ala Ser Glu Asp Thr Phe Ser Ser Tyr
20 25 30

20

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25

Gly Arg Ile Ile Pro Ile Ile Gly Ile Val Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Cys Thr Ala Tyr
65 70 75 80

30

Met Glu Leu Thr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

35

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

40

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

45

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

50

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205

55

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220

EP 2 625 201 B1

	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225						230				235					240	
5	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
10	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
15	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
20	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
	290						295					300					
25	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
30	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
35	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
40	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
45	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
	370						375					380					
50	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
	385					390					395					400	
55	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
					405					410					415		
60	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
65	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
70	Lys																

<210> 126
 <211> 449
 <212> PRT

EP 2 625 201 B1

<213> Artificial

<220>

<223> VH

5

<400> 126

10

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

20

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25

Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Tyr Thr Ala Tyr
65 70 75 80

30

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Val Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly
100 105 110

35

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

40

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

45

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

50

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

55

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220

EP 2 625 201 B1

	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225						230				235					240	
5	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
10	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
15	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
20	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
	290						295					300					
25	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
30	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
35	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
40	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
45	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
	370						375					380					
50	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
	385					390					395					400	
55	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
					405					410					415		
60	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
65	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
70	Lys																

<210> 127
 <211> 213
 <212> PRT

EP 2 625 201 B1

<213> Artificial

<220>

<223> VL

5

<400> 127

10

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Val
20 25 30

20

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

25

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

30

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110

35

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125

40

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160

45

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

50

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

55

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

Asn Arg Gly Glu Cys
210

EP 2 625 201 B1

<210> 128
<211> 213
<212> PRT
<213> Artificial

5

<220>
<223> VL

10

<400> 128

15

20

25

30

35

40

45

50

55

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

EP 2 625 201 B1

Asn Arg Gly Glu Cys
210

5 <210> 129
<211> 213
<212> PRT
<213> Artificial

10 <220>
<223> VL

<400> 129

15

20

25

30

35

40

45

50

55

EP 2 625 201 B1

[illegible]

EP 2 625 201 B1

<220>

<223> VL

<400> 130

5	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	1	5	10	15
10	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val	20	25	30	
15	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	35	40	45	
20	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	50	55	60	
25	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	65	70	75	80
30	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr	85	90	95	
35	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	100	105	110	
40	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	115	120	125	
45	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	130	135	140	
50	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	145	150	155	160
55	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	165	170	175	
	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	180	185	190	
	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	195	200	205	
	Asn	Arg	Gly	Glu	Cys												210			

<210> 131

<211> 213

EP 2 625 201 B1

<212> PRT
<213> Artificial

<220>
<223> VL

<400> 131

10	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	1	5	10	15
15	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val	20	25	30	
20	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	35	40	45	
25	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	50	55	60	
30	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	65	70	75	80
35	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asp	Ser	Ser	Ile	Thr	85	90	95	
40	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	100	105	110	
45	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	115	120	125	
50	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	130	135	140	
55	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	145	150	155	160
	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	165	170	175	

EP 2 625 201 B1

	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala
				180					185					190		
5	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe
			195					200					205			
10	Asn	Arg	Gly	Glu	Cys											
		210														
	<210> 132															
	<211> 213															
	<212> PRT															
15	<213> Artificial															
	<220>															
	<223> VL															
20	<400> 132															
	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
25	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
30	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
35	Tyr	Asp	Ala	Ser	Arg	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
40	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
45	Glu	Asp	Phe	Thr	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Tyr	Thr
					85					90					95	
50	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro
				100					105					110		
55	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
			115					120					125			
60	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
		130					135					140				
65	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu
	145					150					155					160

EP 2 625 201 B1

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

5 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

10 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

Asn Arg Gly Glu Cys
210

15
<210> 133
<211> 213
<212> PRT
<213> Artificial

20
<220>
<223> VL

25
<400> 133

30

35

40

45

50

55

EP 2 625 201 B1

[illegible]

EP 2 625 201 B1

<220>

<223> VL

<400> 134

5

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

10

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Val
20 25 30

15

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

20

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

25

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asp Ser Ser Ile Thr
85 90 95

30

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125

35

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140

40

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

45

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

50

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

55

Asn Arg Gly Glu Cys
210

<210> 135

<211> 213

EP 2 625 201 B1

<212> PRT
<213> Artificial

<220>
<223> VL

<400> 135

10	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
15	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Val
				20					25					30		
20	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
25	Tyr	Ala	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
30	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
35	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
40	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro
				100					105					110		
45	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
			115					120					125			

EP 2 625 201 B1

	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
	130						135					140				
5	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu
	145					150					155					160
10	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser
					165					170					175	
15	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala
				180					185					190		
20	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe
		195						200					205			
25	Asn	Arg	Gly	Glu	Cys											
	210															
	<210>	136														
	<211>	213														
	<212>	PRT														
	<213>	Artificial														
	<220>															
	<223>	VL														
30	<400>	136														
35	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
40	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala
				20					25					30		
45	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile
			35					40					45			
50	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50						55					60				
55	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75				80	
	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
60	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro
				100					105					110		

EP 2 625 201 B1

	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
			115					120					125			
5	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
		130					135					140				
10	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu
	145					150					155					160
15	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser
				165					170						175	
20	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala
				180					185					190		
25	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe
		195						200					205			
30	Asn	Arg	Gly	Glu	Cys											
		210														
	<210> 137															
	<211> 213															
	<212> PRT															
	<213> Artificial															
	<220>															
	<223> VL															
35	<400> 137															
40																
45																
50																
55																

EP 2 625 201 B1

	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	
	1				5					10					15		
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala	
				20					25					30			
10	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile	
			35					40					45				
15	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	
		50					55					60					
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	
		65				70					75					80	
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr	
					85					90					95		
30	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	
				100					105					110			
35	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	
			115					120					125				
40	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	
		130					135					140					
45	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	
		145				150					155					160	
50	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	
					165					170					175		
55	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	
				180					185					190			
	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	
			195					200					205				
	Asn	Arg	Gly	Glu	Cys												
			210														
55	<210>	138															
	<211>	213															
	<212>	PRT															
	<213>	Artificial															

EP 2 625 201 B1

<220>

<223> VL

<400> 138

5

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

10

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
20 25 30

15

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Met Ile
35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

20

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

25

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Ser Ile Thr
85 90 95

30

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
100 105 110

Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
115 120 125

35

Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
130 135 140

40

Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
145 150 155 160

45

Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
165 170 175

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
180 185 190

50

Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
195 200 205

55

Asn Arg Gly Glu Cys
210

<210> 139

EP 2 625 201 B1

<211> 213
 <212> PRT
 <213> Artificial

5 <220>
 <223> VL

<400> 139

10 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
 20 25 30

20 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Met Ile
 35 40 45

25 Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

30 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

35

40

45

50

55

EP 2 625 201 B1

	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr	
					85					90					95		
5	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro	
				100					105					110			
10	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	
			115					120					125				
15	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	
		130					135					140					
20	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	
	145					150					155					160	
25	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	
					165					170					175		
30	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	
				180					185					190			
35	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	
			195					200					205				
40	Asn	Arg	Gly	Glu	Cys												
		210															
45	<210>	140															
	<211>	213															
	<212>	PRT															
	<213>	Artificial															
50	<220>																
	<223>	VL															
55	<400>	140															
60	Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	
	1				5					10					15		
65	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly	Ile	Ser	Ser	Ala	
				20					25					30			
70	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Phe	Met	Ile	
			35					40					45				
75	Tyr	Asp	Ala	Ser	Ser	Leu	Glu	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	
		50					55					60					

EP 2 625 201 B1

	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75				80	
5	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Phe	Asn	Ser	Ser	Ile	Thr
					85					90					95	
10	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala	Pro
				100					105					110		
15	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
			115					120					125			
20	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
	130						135					140				
25	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu
	145					150					155					160
30	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser
					165					170					175	
35	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala
				180					185					190		
40	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe
			195					200					205			
45	Asn	Arg	Gly	Glu	Cys											
			210													
50	<210> 141															
	<211> 18															
	<212> PRT															
	<213> Artificial															
55	<220>															
	<223> Epitope range															
	<400> 141															
	Phe	Phe	His	Pro	Ile	Pro	Tyr	Tyr	Asp	Lys	Asn	Ser	Pro	Val	His	Gly
	1				5					10					15	
	Tyr Trp															
	<210> 142															
	<211> 11															
	<212> PRT															
	<213> Artificial															
	<220>															

<400> 142

5 Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu
1 5 10

Claims

- 116

15. A CD33 binding agent according to any of claim 12-14, wherein the mutations in the F_c domain are a combination of substitutions at positions 239 and 332, preferably S239D/I332E.

16. A CD33 binding agent selected from

an antibody comprising a CDR1 of SeqID No: 1, a CDR2 of SeqID No: 15, a CDR3 of SeqID No: 29, a CDR4 of SeqID No: 43, a CDR5 of SeqID No: 57 and a CDR6 of SeqID No: 71,
 an antibody comprising a CDR1 of SeqID No: 2, a CDR2 of SeqID No: 16, a CDR3 of SeqID No: 30, a CDR4 of SeqID No: 44, a CDR5 of SeqID No: 58 and a CDR6 of SeqID No: 72,
 an antibody comprising a CDR1 of SeqID No: 3, a CDR2 of SeqID No: 17, a CDR3 of SeqID No: 31, a CDR4 of SeqID No: 45, a CDR5 of SeqID No: 59 and a CDR6 of SeqID No: 73,
 an antibody comprising a CDR1 of SeqID No: 4, a CDR2 of SeqID No: 18, a CDR3 of SeqID No: 32, a CDR4 of SeqID No: 46, a CDR5 of SeqID No: 60 and a CDR6 of SeqID No: 74,
 an antibody comprising a CDR1 of SeqID No: 5, a CDR2 of SeqID No: 19, a CDR3 of SeqID No: 33, a CDR4 of SeqID No: 47, a CDR5 of SeqID No: 61 and a CDR6 of SeqID No: 75,
 an antibody comprising a CDR1 of SeqID No: 6, a CDR2 of SeqID No: 20, a CDR3 of SeqID No: 34, a CDR4 of SeqID No: 48, a CDR5 of SeqID No: 62 and a CDR6 of SeqID No: 76,
 an antibody comprising a CDR1 of SeqID No: 7, a CDR2 of SeqID No: 21, a CDR3 of SeqID No: 35, a CDR4 of SeqID No: 49, a CDR5 of SeqID No: 63 and a CDR6 of SeqID No: 77,
 an antibody comprising a CDR1 of SeqID No: 8, a CDR2 of SeqID No: 22, a CDR3 of SeqID No: 36, a CDR4 of SeqID No: 50, a CDR5 of SeqID No: 64 and a CDR6 of SeqID No: 78,
 an antibody comprising a CDR1 of SeqID No: 9, a CDR2 of SeqID No: 23, a CDR3 of SeqID No: 37, a CDR4 of SeqID No: 51, a CDR5 of SeqID No: 65 and a CDR6 of SeqID No: 79,
 an antibody comprising a CDR1 of SeqID No: 10, a CDR2 of SeqID No: 24, a CDR3 of SeqID No: 38, a CDR4 of SeqID No: 52, a CDR5 of SeqID No: 66 and a CDR6 of SeqID No: 80,
 an antibody comprising a CDR1 of SeqID No: 11, a CDR2 of SeqID No: 25, a CDR3 of SeqID No: 39, a CDR4 of SeqID No: 53, a CDR5 of SeqID No: 67 and a CDR6 of SeqID No: 81,
 an antibody comprising a CDR1 of SeqID No: 12, a CDR2 of SeqID No: 26, a CDR3 of SeqID No: 40, a CDR4 of SeqID No: 54, a CDR5 of SeqID No: 68 and a CDR6 of SeqID No: 82,
 an antibody comprising a CDR1 of SeqID No: 13, a CDR2 of SeqID No: 27, a CDR3 of SeqID No: 41, a CDR4 of SeqID No: 55, a CDR5 of SeqID No: 69 and a CDR6 of SeqID No: 83,
 an antibody comprising a CDR1 of SeqID No: 14, a CDR2 of SeqID No: 28, a CDR3 of SeqID No: 42, a CDR4 of SeqID No: 56, a CDR5 of SeqID No: 70 and a CDR6 of SeqID No: 84.

17. A CD33 binding agent selected from

an antibody comprising a heavy chain variable region of SeqID No: 85 and a light chain variable region of SeqID No: 99,
 an antibody comprising a heavy chain variable region of SeqID No: 86 and a light chain variable region of SeqID No: 100,
 an antibody comprising a heavy chain variable region of SeqID No: 87 and a light chain variable region of SeqID No: 101,
 an antibody comprising a heavy chain variable region of SeqID No: 88 and a light chain variable region of SeqID No: 102,
 an antibody comprising a heavy chain variable region of SeqID No: 89 and a light chain variable region of SeqID No: 103,
 an antibody comprising a heavy chain variable region of SeqID No: 90 and a light chain variable region of SeqID No: 104,
 an antibody comprising a heavy chain variable region of SeqID No: 91 and a light chain variable region of SeqID No: 105,
 an antibody comprising a heavy chain variable region of SeqID No: 92 and a light chain variable region of SeqID No: 106,
 an antibody comprising a heavy chain variable region of SeqID No: 93 and a light chain variable region of SeqID No: 107,
 an antibody comprising a heavy chain variable region of SeqID No: 94 and a light chain variable region of SeqID No: 108,
 an antibody comprising a heavy chain variable region of SeqID No: 95 and a light chain variable region of SeqID No: 109,

an antibody comprising a heavy chain variable region of SeqID No: 96 and a light chain variable region of SeqID No: 110,
 an antibody comprising a heavy chain variable region of SeqID No: 97 and a light chain variable region of SeqID No: 111,
 5 an antibody comprising a heavy chain variable region of SeqID No: 98 and a light chain variable region of SeqID No: 112,

18. A CD33 binding agent selected from

10 an antibody comprising a heavy chain of SeqID No: 113 and a light chain of SeqID No: 127,
 an antibody comprising a heavy chain of SeqID No: 114 and a light chain of SeqID No: 128,
 an antibody comprising a heavy chain of SeqID No: 115 and a light chain of SeqID No: 129,
 an antibody comprising a heavy chain of SeqID No: 116 and a light chain of SeqID No: 130,
 an antibody comprising a heavy chain of SeqID No: 117 and a light chain of SeqID No: 131,
 15 an antibody comprising a heavy chain of SeqID No: 118 and a light chain of SeqID No: 132,
 an antibody comprising a heavy chain of SeqID No: 119 and a light chain of SeqID No: 133,
 an antibody comprising a heavy chain of SeqID No: 120 and a light chain of SeqID No: 134,
 an antibody comprising a heavy chain of SeqID No: 121 and a light chain of SeqID No: 135,
 an antibody comprising a heavy chain of SeqID No: 122 and a light chain of SeqID No: 136,
 20 an antibody comprising a heavy chain of SeqID No: 123 and a light chain of SeqID No: 137,
 an antibody comprising a heavy chain of SeqID No: 124 and a light chain of SeqID No: 138,
 an antibody comprising a heavy chain of SeqID No: 125 and a light chain of SeqID No: 139,
 an antibody comprising a heavy chain of SeqID No: 126 and a light chain of SeqID No: 140.

25 **19. A CD33 binding agent according to any of claims 16 to 18, wherein the CD33 binding agent further comprises an effector function.**

20. A CD33 binding agent according to claim 19, wherein the effector function is mediated by an F_c domain.

30 **21. A CD33 binding agent according to claim 19, wherein the CD33 binding agent comprises one or more mutations in the F_c domain that modulate the function of the F_c domain.**

22. A CD33 binding agent according to claim 21, wherein the modulation of the function of the F_c domain is an increase of ADCC by at least 10%, preferably 50% and more preferably 100%.

35 **23. A CD33 binding agent according to any of claim 21-22, wherein the mutations in the F_c domain are located at one or more positions selected from amino acids at positions 332 and/or 239 and/or 236 according to the Kabat EU numbering index.**

40 **24. A CD33 binding agent according to any of claim 21-23, wherein the mutations in the F_c domain are a combination of substitutions at positions 239 and 332, preferably S239D/I332E.**

25. A DNA molecule comprising a region encoding the heavy chain variable region of a CD33 binding agent according to any of the preceding claims.

45 **26. A DNA molecule comprising a region encoding the light chain variable region of a CD33 binding agent according to any of claims 1-24.**

27. An expression vector containing a DNA molecule of claim 25 or 26.

50 **28. A host cell carrying one or more vectors of claim 27.**

29. A method for producing a CD33 binding agent of any one of claims 1-24, comprising transfecting a host cell with one or more vectors of claim 27, culturing the host cell and recovering and purifying the antibody molecule.

55 **30. A pharmaceutical composition comprising, as the active ingredient, one or more CD33 binding agents according to any one of claims 1 to 24, and at least a physiologically acceptable carrier.**

31. The pharmaceutical composition of claim 30, further comprising one or more additional therapeutic agents.
32. The pharmaceutical composition of any one of claims 30-31 for depleting cells that express CD33 on their surface.
33. The pharmaceutical composition of any one of claims 30-31 for use in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
34. The pharmaceutical composition for the use of claim 33, wherein said myeloid malignancy is selected from acute myeloid leukemia and chronic myeloid leukemia.
35. The pharmaceutical composition of any one of claims 30-31 for the use in the treatment of autoimmune and inflammatory diseases that involve myeloid cells in their pathology.

Patentansprüche

1. CD33-bindendes Agens, das an Human-CD33 bindet, wobei das CD33-bindende Agens ein Antikörper oder ein Derivat von einem Antikörper, definiert durch das spezifische Binden an ein Epitop innerhalb der Aminosäuresequenz FFHPIPYDYKNSPVHGYW (SeqID No: 141) von Human-CD33, ist.
2. CD33-bindendes Agens nach Anspruch 1, **dadurch gekennzeichnet, dass** es eine variable Region einer schweren Kette umfassend CDR1, CDR2 und CDR3 und eine variable Region einer leichten Kette umfassend CDR4, CDR5 und CDR6 aufweist, wobei CDR1 eine Aminosäuresequenz ausgewählt aus SeqID No:1-14 aufweist, CDR2 eine Aminosäuresequenz ausgewählt aus SeqID No:15-28 aufweist, CDR3 eine Aminosäuresequenz ausgewählt aus SeqID No:29-42 aufweist, CDR4 eine Aminosäuresequenz ausgewählt aus SeqID No:43-56 aufweist, CDR5 eine Aminosäuresequenz ausgewählt aus SeqID No:57-70 aufweist, CDR6 eine Aminosäuresequenz ausgewählt aus SeqID No:71-84 aufweist.
3. CD33-bindendes Agens nach Anspruch 1 oder 2, wobei das Epitop durch Wasserstoffaustausch-Massenspektroskopie bestimmt wird.
4. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei die Internalisierungskinetik der CD33-bindenden Agenzien so ist, dass zu einem Zeitpunkt von 4 Stunden nach Inkubation mindestens 40% der anfänglichen Menge der CD33-bindenden Agenzien auf der Zelloberfläche verbleiben.
5. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei die variable Region der schweren Kette eine Aminosäuresequenz ausgewählt aus SeqID No:85-98 umfasst und die variable Region der leichten Kette eine Aminosäuresequenz ausgewählt aus SeqID No:99-112 umfasst.
6. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei das CD33-bindende Agens eine schwere Kette mit einer Aminosäuresequenz ausgewählt aus SeqID No:113-126 und eine leichte Kette mit einer Aminosäuresequenz ausgewählt aus SeqID No:127-140 aufweist.
7. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei das CD33-bindende Agens sowohl zu Human-CD33 als auch zu Cynomolgus-CD33 eine Affinität mit einer K_D von gleich oder weniger als 10 nM aufweist.
8. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei das CD33-bindende Agens humanisiert ist.
9. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei das CD33-bindende Agens vollständig human ist.
10. CD33-bindendes Agens nach irgendeinem der vorhergehenden Ansprüche, wobei das CD33-bindende Agens ferner eine Effektorfunktion umfasst.
11. CD33-bindendes Agens nach Anspruch 10, wobei die Effektorfunktion durch eine F_c -Domäne vermittelt wird.

12. CD33-bindendes Agens nach Anspruch 10, wobei das CD33-bindende Agens eine oder mehrere Mutationen in der F_C-Domäne umfasst, was die Funktion der F_C-Domäne moduliert.

13. CD33-bindendes Agens nach Anspruch 12, wobei die Modulation der Funktion der F_C-Domäne eine Steigerung der ADCC um mindestens 10%, bevorzugt 50% und mehr, bevorzugt 100% ist.

14. CD33-bindendes Agens nach irgendeinem der Ansprüche 12-13, wobei die Mutationen in der F_C-Domäne an einer oder mehreren Positionen ausgewählt aus Aminosäuren an den Positionen 332 und/oder 239 und/oder 236 gemäß dem Kabat-EU-Numerierungsindex lokalisiert sind.

15. CD33-bindendes Agens nach irgendeinem der Ansprüche 12-14, wobei die Mutationen in der F_C-Domäne eine Kombination von Substitutionen an den Positionen 239 und 332, bevorzugt S239D/I332E, sind.

16. CD33-bindendes Agens, ausgewählt aus

einem Antikörper umfassend eine CDR1 von SeqID No: 1, eine CDR2 von SeqID No: 15, eine CDR3 von SeqID No: 29, eine CDR4 von SeqID No: 43, eine CDR5 von SeqID No: 57 und eine CDR6 von SeqID No: 71, einem Antikörper umfassend eine CDR1 von SeqID No: 2, eine CDR2 von SeqID No: 16, eine CDR3 von SeqID No: 30, eine CDR4 von SeqID No: 44, eine CDR5 von SeqID No: 58 und eine CDR6 von SeqID No: 72, einem Antikörper umfassend eine CDR1 von SeqID No: 3, eine CDR2 von SeqID No: 17, eine CDR3 von SeqID No: 31, eine CDR4 von SeqID No: 45, eine CDR5 von SeqID No: 59 und eine CDR6 von SeqID No: 73, einem Antikörper umfassend eine CDR1 von SeqID No: 4, eine CDR2 von SeqID No: 18, eine CDR3 von SeqID No: 32, eine CDR4 von SeqID No: 46, eine CDR5 von SeqID No: 60 und eine CDR6 von SeqID No: 74, einem Antikörper umfassend eine CDR1 von SeqID No: 5, eine CDR2 von SeqID No: 19, eine CDR3 von SeqID No: 33, eine CDR4 von SeqID No: 47, eine CDR5 von SeqID No: 61 und eine CDR6 von SeqID No: 75, einem Antikörper umfassend eine CDR1 von SeqID No: 6, eine CDR2 von SeqID No: 20, eine CDR3 von SeqID No: 34, eine CDR4 von SeqID No: 48, eine CDR5 von SeqID No: 62 und eine CDR6 von SeqID No: 76, einem Antikörper umfassend eine CDR1 von SeqID No: 7, eine CDR2 von SeqID No: 21, eine CDR3 von SeqID No: 35, eine CDR4 von SeqID No: 49, eine CDR5 von SeqID No: 63 und eine CDR6 von SeqID No: 77, einem Antikörper umfassend eine CDR1 von SeqID No: 8, eine CDR2 von SeqID No: 22, eine CDR3 von SeqID No: 36, eine CDR4 von SeqID No: 50, eine CDR5 von SeqID No: 64 und eine CDR6 von SeqID No: 78, einem Antikörper umfassend eine CDR1 von SeqID No: 9, eine CDR2 von SeqID No: 23, eine CDR3 von SeqID No: 37, eine CDR4 von SeqID No: 51, eine CDR5 von SeqID No: 65 und eine CDR6 von SeqID No: 79, einem Antikörper umfassend eine CDR1 von SeqID No: 10, eine CDR2 von SeqID No: 24, eine CDR3 von SeqID No: 38, eine CDR4 von SeqID No: 52, eine CDR5 von SeqID No: 66 und eine CDR6 von SeqID No: 80, einem Antikörper umfassend eine CDR1 von SeqID No: 11, eine CDR2 von SeqID No: 25, eine CDR3 von SeqID No: 39, eine CDR4 von SeqID No: 53, eine CDR5 von SeqID No: 67 und eine CDR6 von SeqID No: 81, einem Antikörper umfassend eine CDR1 von SeqID No: 12, eine CDR2 von SeqID No: 26, eine CDR3 von SeqID No: 40, eine CDR4 von SeqID No: 54, eine CDR5 von SeqID No: 68 und eine CDR6 von SeqID No: 82, einem Antikörper umfassend eine CDR1 von SeqID No: 13, eine CDR2 von SeqID No: 27, eine CDR3 von SeqID No: 41, eine CDR4 von SeqID No: 55, eine CDR5 von SeqID No: 69 und eine CDR6 von SeqID No: 83, einem Antikörper umfassend eine CDR1 von SeqID No: 14, eine CDR2 von SeqID No: 28, eine CDR3 von SeqID No: 42, eine CDR4 von SeqID No: 56, eine CDR5 von SeqID No: 70 und eine CDR6 von SeqID No: 84.

17. CD33-bindendes Agens, ausgewählt aus

einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 85 und eine variable Region einer leichten Kette von SeqID No: 99, einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 86 und eine variable Region einer leichten Kette von SeqID No: 100, einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 87 und eine variable Region einer leichten Kette von SeqID No: 101, einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 88 und eine variable Region einer leichten Kette von SeqID No: 102, einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 89 und eine variable Region einer leichten Kette von SeqID No: 103, einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 90 und eine variable Region einer leichten Kette von SeqID No: 104,

einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 91 und eine variable Region einer leichten Kette von SeqID No: 105,
 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 92 und eine variable Region einer leichten Kette von SeqID No: 106,
 5 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 93 und eine variable Region einer leichten Kette von SeqID No: 107,
 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 94 und eine variable Region einer leichten Kette von SeqID No: 108,
 10 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 95 und eine variable Region einer leichten Kette von SeqID No: 109,
 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 96 und eine variable Region einer leichten Kette von SeqID No: 110,
 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 97 und eine variable Region einer leichten Kette von SeqID No: 111,
 15 einem Antikörper umfassend eine variable Region einer schweren Kette von SeqID No: 98 und eine variable Region einer leichten Kette von SeqID No: 112.

18. CD33-bindendes Agens, ausgewählt aus

20 einem Antikörper umfassend eine schwere Kette von SeqID No: 113 und eine leichte Kette von SeqID No: 127,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 114 und eine leichte Kette von SeqID No: 128,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 115 und eine leichte Kette von SeqID No: 129,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 116 und eine leichte Kette von SeqID No: 130,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 117 und eine leichte Kette von SeqID No: 131,
 25 einem Antikörper umfassend eine schwere Kette von SeqID No: 118 und eine leichte Kette von SeqID No: 132,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 119 und eine leichte Kette von SeqID No: 133,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 120 und eine leichte Kette von SeqID No: 134,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 121 und eine leichte Kette von SeqID No: 135,
 30 einem Antikörper umfassend eine schwere Kette von SeqID No: 122 und eine leichte Kette von SeqID No: 136,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 123 und eine leichte Kette von SeqID No: 137,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 124 und eine leichte Kette von SeqID No: 138,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 125 und eine leichte Kette von SeqID No: 139,
 einem Antikörper umfassend eine schwere Kette von SeqID No: 126 und eine leichte Kette von SeqID No: 140.

35 **19.** CD33-bindendes Agens nach irgendeinem der Ansprüche 16 bis 18, wobei das CD33-bindende Agens ferner eine Effektorfunktion umfasst.

20. CD33-bindendes Agens nach Anspruch 19, wobei die Effektorfunktion durch eine F_c -Domäne vermittelt wird.

40 **21.** CD33-bindendes Agens nach Anspruch 19, wobei das CD33-bindende Agens eine oder mehrere Mutationen in der F_c -Domäne umfasst, was die Funktion der F_c -Domäne moduliert.

22. CD33-bindendes Agens nach Anspruch 21, wobei die Modulation der Funktion der F_c -Domäne eine Steigerung der ADCC um mindestens 10%, bevorzugt 50% und mehr, bevorzugt 100% ist.

45 **23.** CD33-bindendes Agens nach irgendeinem der Ansprüche 21-22, wobei die Mutationen in der F_c -Domäne an einer oder mehreren Positionen ausgewählt aus Aminosäuren an den Positionen 332 und/oder 239 und/oder 236 gemäß dem Kabat-EU-Numerierungsindex lokalisiert sind.

50 **24.** CD33-bindendes Agens nach irgendeinem der Ansprüche 21-23, wobei die Mutationen in der F_c -Domäne eine Kombination von Substitutionen an den Positionen 239 und 332, bevorzugt S239D/I332E, sind.

25. DNA-Molekül, umfassend eine Region, die die variable Region einer schweren Kette eines CD33-bindenden Agens nach irgendeinem der vorhergehenden Ansprüche kodiert.

55 **26.** DNA-Molekül, umfassend eine Region, die die variable Region einer leichten Kette eines CD33-bindenden Agens nach irgendeinem der Ansprüche 1-24 kodiert.

27. Expressionsvektor, enthaltend ein DNA-Molekül nach Anspruch 25 oder 26.

28. Wirtszelle, die einen oder mehrere Vektoren nach Anspruch 27 enthält.

29. Verfahren zur Herstellung eines CD33-bindenden Agens nach irgendeinem der Ansprüche 1-24, umfassend das Transfizieren einer Wirtszelle mit einem oder mehreren Vektoren nach Anspruch 27, das Kultivieren der Wirtszelle und das Gewinnen und Reinigen des Antikörpermoleküls.

30. Pharmazeutische Zusammensetzung, umfassend als den Wirkstoff ein oder mehrere CD33-bindende Agenzien nach irgendeinem der Ansprüche 1 bis 24 und mindestens einen physiologisch akzeptablen Träger.

31. Pharmazeutische Zusammensetzung nach Anspruch 30, ferner umfassend ein oder mehrere zusätzliche Therapeutika.

32. Pharmazeutische Zusammensetzung nach irgendeinem der Ansprüche 30-31 zur Depletion von Zellen, die CD33 auf ihrer Oberfläche exprimieren.

33. Pharmazeutische Zusammensetzung nach irgendeinem der Ansprüche 30-31 zur Verwendung bei der Behandlung von Myeloidzell-Malignität und myelodysplastischem Syndrom (MDS).

34. Pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 33, wobei die myeloische Malignität ausgewählt ist aus akuter myeloischer Leukämie und chronischer myeloischer Leukämie.

35. Pharmazeutische Zusammensetzung nach irgendeinem der Ansprüche 30-31 zur Verwendung bei der Behandlung von Autoimmun- und Entzündungserkrankungen, in deren Pathologie myeloische Zellen involviert sind.

Revendications

1. Agent de liaison au CD33 se liant au CD33 humain, l'agent de liaison au CD33 étant un anticorps ou un dérivé d'un anticorps, défini par une liaison spécifique à un épitope au sein de la séquence d'acides aminés FFHPIPYDKNS-PVHGYW (SEQ ID No : 141) du CD33 humain.

2. Agent de liaison au CD33 selon la revendication 1, **caractérisé en ce qu'il** possède une région variable de chaîne lourde comprenant CDR1, CDR2 et CDR3, et une région variable de chaîne légère comprenant CDR4, CDR5 et CDR6, dans laquelle CDR1 possède une séquence d'acides aminés choisie parmi SEQ ID No : 1-14, CDR2 possède une séquence d'acides aminés choisie parmi SEQ ID No : 15-28, CDR3 possède une séquence d'acides aminés choisie parmi SEQ ID No : 29-42, CDR4 possède une séquence d'acides aminés choisie parmi SEQ ID No : 43-56, CDR5 possède une séquence d'acides aminés choisie parmi SEQ ID No : 57-70, CDR6 possède une séquence d'acides aminés choisie parmi SEQ ID No : 71-84.

3. Agent de liaison au CD33 selon la revendication 1 ou 2, dans lequel l'épitope est déterminé par spectrométrie de masse avec échange d'hydrogène.

4. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel les cinétiques d'internalisation des agents de liaison au CD33 sont telles qu'au moins 40 % de la quantité initiale des agents de liaison au CD33 reste sur la surface cellulaire à un temps de 4 heures après l'incubation.

5. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel la région variable de chaîne lourde comprend une séquence d'acides aminés choisie parmi SEQ ID No : 85-98 et la région variable de chaîne légère comprend une séquence d'acides aminés choisie parmi SEQ ID No : 99-112.

6. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel l'agent de liaison au CD33 possède une chaîne lourde ayant une séquence d'acides aminés choisie parmi SEQ ID No : 113-126 et une chaîne légère ayant une séquence d'acides aminés choisie parmi SEQ ID No : 127-140.

7. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel l'agent de liaison au CD33 possède une affinité vis-à-vis à la fois du CD33 humain et du CD33 de macaque cynomolgus présentant

un K_D inférieur ou égal à 10 nM.

8. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel l'agent de liaison au CD33 est humanisé.

9. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel l'agent de liaison au CD33 est entièrement humain.

10. Agent de liaison au CD33 selon l'une quelconque des revendications précédentes, dans lequel l'agent de liaison au CD33 comprend en outre une fonction effectrice.

11. Agent de liaison au CD33 selon la revendication 10, dans lequel la fonction effectrice est assurée par un domaine F_c .

12. Agent de liaison au CD33 selon la revendication 10, dans lequel l'agent de liaison au CD33 comprend une ou plusieurs mutations dans le domaine F_c qui modulent la fonction du domaine F_c .

13. Agent de liaison au CD33 selon la revendication 12, dans lequel la modulation de la fonction du domaine F_c est une hausse d'ADCC d'au moins 10 %, de préférence de 50 % et de façon plus préférée de 100 %.

14. Agent de liaison au CD33 selon l'une quelconque des revendications 12-13, dans lequel les mutations dans le domaine F_c sont situées sur une ou plusieurs positions choisies parmi les acides aminés sur les positions 332 et/ou 239 et/ou 236 selon l'index de numérotation EU de Kabat.

15. Agent de liaison au CD33 selon l'une quelconque des revendications 12-14, dans lequel les mutations dans le domaine F_c sont une combinaison de substitutions sur les positions 239 et 332, de préférence S239D/I332E.

16. Agent de liaison au CD33 choisi parmi

un anticorps comprenant une CDR1 de SEQ ID No : 1, une CDR2 de SEQ ID No : 15, une CDR3 de SEQ ID No : 29, une CDR4 de SEQ ID No : 43, une CDR5 de SEQ ID No : 57 et une CDR6 de SEQ ID No : 71,
un anticorps comprenant une CDR1 de SEQ ID No : 2, une CDR2 de SEQ ID No : 16, une CDR3 de SEQ ID No : 30, une CDR4 de SEQ ID No : 44, une CDR5 de SEQ ID No : 58 et une CDR6 de SEQ ID No : 72,
un anticorps comprenant une CDR1 de SEQ ID No : 3, une CDR2 de SEQ ID No : 17, une CDR3 de SEQ ID No : 31, une CDR4 de SEQ ID No : 45, une CDR5 de SEQ ID No : 59 et une CDR6 de SEQ ID No : 73,
un anticorps comprenant une CDR1 de SEQ ID No : 4, une CDR2 de SEQ ID No : 18, une CDR3 de SEQ ID No : 32, une CDR4 de SEQ ID No : 46, une CDR5 de SEQ ID No : 60 et une CDR6 de SEQ ID No : 74,
un anticorps comprenant une CDR1 de SEQ ID No : 5, une CDR2 de SEQ ID No : 19, une CDR3 de SEQ ID No : 33, une CDR4 de SEQ ID No : 47, une CDR5 de SEQ ID No : 61 et une CDR6 de SEQ ID No : 75,
un anticorps comprenant une CDR1 de SEQ ID No : 6, une CDR2 de SEQ ID No : 20, une CDR3 de SEQ ID No : 34, une CDR4 de SEQ ID No : 48, une CDR5 de SEQ ID No : 62 et une CDR6 de SEQ ID No : 76,
un anticorps comprenant une CDR1 de SEQ ID No : 7, une CDR2 de SEQ ID No : 21, une CDR3 de SEQ ID No : 35, une CDR4 de SEQ ID No : 49, une CDR5 de SEQ ID No : 63 et une CDR6 de SEQ ID No : 77,
un anticorps comprenant une CDR1 de SEQ ID No : 8, une CDR2 de SEQ ID No : 22, une CDR3 de SEQ ID No : 36, une CDR4 de SEQ ID No : 50, une CDR5 de SEQ ID No : 64 et une CDR6 de SEQ ID No : 78,
un anticorps comprenant une CDR1 de SEQ ID No : 9, une CDR2 de SEQ ID No : 23, une CDR3 de SEQ ID No : 37, une CDR4 de SEQ ID No : 51, une CDR5 de SEQ ID No : 65 et une CDR6 de SEQ ID No : 79,
un anticorps comprenant une CDR1 de SEQ ID No : 10, une CDR2 de SEQ ID No : 24, une CDR3 de SEQ ID No : 38, une CDR4 de SEQ ID No : 52, une CDR5 de SEQ ID No : 66 et une CDR6 de SEQ ID No : 80,
un anticorps comprenant une CDR1 de SEQ ID No : 11, une CDR2 de SEQ ID No : 25, une CDR3 de SEQ ID No : 39, une CDR4 de SEQ ID No : 53, une CDR5 de SEQ ID No : 67 et une CDR6 de SEQ ID No : 81,
un anticorps comprenant une CDR1 de SEQ ID No : 12, une CDR2 de SEQ ID No : 26, une CDR3 de SEQ ID No : 40, une CDR4 de SEQ ID No : 54, une CDR5 de SEQ ID No : 68 et une CDR6 de SEQ ID No : 82,
un anticorps comprenant une CDR1 de SEQ ID No : 13, une CDR2 de SEQ ID No : 27, une CDR3 de SEQ ID No : 41, une CDR4 de SEQ ID No : 55, une CDR5 de SEQ ID No : 69 et une CDR6 de SEQ ID No : 83,
un anticorps comprenant une CDR1 de SEQ ID No : 14, une CDR2 de SEQ ID No : 28, une CDR3 de SEQ ID No : 42, une CDR4 de SEQ ID No : 56, une CDR5 de SEQ ID No : 70 et une CDR6 de SEQ ID No : 84.

17. Agent de liaison au CD33 choisi parmi

un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 85 et une région variable de chaîne légère de SEQ ID No : 99,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 86 et une région variable de chaîne légère de SEQ ID No : 100,
 5 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 87 et une région variable de chaîne légère de SEQ ID No : 101,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 88 et une région variable de chaîne légère de SEQ ID No : 102,
 10 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 89 et une région variable de chaîne légère de SEQ ID No : 103,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 90 et une région variable de chaîne légère de SEQ ID No : 104,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 91 et une région variable de chaîne légère de SEQ ID No : 105,
 15 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 92 et une région variable de chaîne légère de SEQ ID No : 106,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 93 et une région variable de chaîne légère de SEQ ID No : 107,
 20 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 94 et une région variable de chaîne légère de SEQ ID No : 108,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 95 et une région variable de chaîne légère de SEQ ID No : 109,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 96 et une région variable de chaîne légère de SEQ ID No : 110,
 25 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 97 et une région variable de chaîne légère de SEQ ID No : 111,
 un anticorps comprenant une région variable de chaîne lourde de SEQ ID No : 98 et une région variable de chaîne légère de SEQ ID No : 112.

18. Agent de liaison au CD33 choisi parmi

un anticorps comprenant une chaîne lourde de SEQ ID No : 113 et une chaîne légère de SEQ ID No : 127,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 114 et une chaîne légère de SEQ ID No : 128,
 35 un anticorps comprenant une chaîne lourde de SEQ ID No : 115 et une chaîne légère de SEQ ID No : 129,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 116 et une chaîne légère de SEQ ID No : 130,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 117 et une chaîne légère de SEQ ID No : 131,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 118 et une chaîne légère de SEQ ID No : 132,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 119 et une chaîne légère de SEQ ID No : 133,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 120 et une chaîne légère de SEQ ID No : 134,
 40 un anticorps comprenant une chaîne lourde de SEQ ID No : 121 et une chaîne légère de SEQ ID No : 135,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 122 et une chaîne légère de SEQ ID No : 136,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 123 et une chaîne légère de SEQ ID No : 137,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 124 et une chaîne légère de SEQ ID No : 138,
 45 un anticorps comprenant une chaîne lourde de SEQ ID No : 125 et une chaîne légère de SEQ ID No : 139,
 un anticorps comprenant une chaîne lourde de SEQ ID No : 126 et une chaîne légère de SEQ ID No : 140.

19. Agent de liaison au CD33 selon l'une quelconque des revendications 16 à 18, dans lequel l'agent de liaison au CD33 comprend en outre une fonction effectrice.

20. Agent de liaison au CD33 selon la revendication 19, dans lequel la fonction effectrice est assurée par un domaine F_c .

21. Agent de liaison au CD33 selon la revendication 19, dans lequel l'agent de liaison au CD33 comprend une ou plusieurs mutations dans le domaine F_c qui modulent la fonction du domaine F_c .

22. Agent de liaison au CD33 selon la revendication 21, dans lequel la modulation de la fonction du domaine F_c est une hausse d'ADCC d'au moins 10 %, de préférence de 50 % et de façon plus préférée de 100 %.

23. Agent de liaison au CD33 selon l'une quelconque des revendications 21-22, dans lequel les mutations dans le

domaine F_c sont situées sur une ou plusieurs positions choisies parmi les acides aminés sur les positions 332 et/ou 239 et/ou 236 selon l'index de numérotation EU de Kabat.

- 5 **24.** Agent de liaison au CD33 selon l'une quelconque des revendications 21-23, dans lequel les mutations dans le domaine F_c sont une combinaison de substitutions sur les positions 239 et 332, de préférence S239D/I332E.
- 25.** Molécule d'ADN comprenant une région codant pour la région variable de chaîne lourde d'un agent de liaison au CD33 selon l'une quelconque des revendications précédentes.
- 10 **26.** Molécule d'ADN comprenant une région codant pour la région variable de chaîne légère d'un agent de liaison au CD33 selon l'une quelconque des revendications 1-24.
- 27.** Vecteur d'expression contenant une molécule d'ADN selon la revendication 25 ou 26.
- 15 **28.** Cellule hôte portant un ou plusieurs vecteurs selon la revendication 27.
- 29.** Méthode de production d'un agent de liaison au CD33 l'une quelconque des revendications 1-24, comprenant la transfection d'une cellule hôte avec un ou plusieurs vecteurs selon la revendication 27, la culture de la cellule hôte et la récupération et la purification de la molécule d'anticorps.
- 20 **30.** Composition pharmaceutique comprenant, en tant qu'ingrédient actif, un ou plusieurs agents de liaison au CD33 l'une quelconque des revendications 1 à 24, et au moins un véhicule physiologiquement acceptable.
- 25 **31.** Composition pharmaceutique selon la revendication 30, comprenant en outre un ou plusieurs agents thérapeutiques supplémentaires.
- 32.** Composition pharmaceutique l'une quelconque des revendications 30-31 permettant d'effectuer la déplétion des cellules qui expriment CD33 sur leur surface.
- 30 **33.** Composition pharmaceutique l'une quelconque des revendications 30-31 pour son utilisation dans le traitement des malignités des cellules myéloïdes et du syndrome myélodysplasique (MDS).
- 34.** Composition pharmaceutique pour son utilisation selon la revendication 33, dans lequel ladite malignité myéloïde est choisie parmi la leucémie myéloïde aiguë et la leucémie myéloïde chronique.
- 35 **35.** Composition pharmaceutique selon l'une quelconque des revendications 30-31 pour son utilisation dans le traitement de maladies autoimmunes et inflammatoires qui font intervenir des cellules myéloïdes dans leur pathologie.

40

45

50

55

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4816567 A, Cabilly [0037]
- US 4816397 A, Boss [0037]
- US 5585089 A [0037]
- WO 8702671 A [0037]
- EP 0184187 A [0037]
- EP 0171496 A [0037]
- EP 0173494 A [0037]
- WO 8601533 A [0037]
- US 012023 A [0037]
- US 5225539 A [0037]
- US 5939598 A [0037]
- US 5770429 A [0037]
- US 5625126 A [0038]
- US 5633425 A [0038]
- US 5569825 A [0038]
- US 5661016 A [0038]
- US 5545806 A [0038]
- US 4946778 A [0040]
- US 20050238646 A [0040]
- US 20060003412 A [0043]
- US 20060008882 A [0043]
- US 20060160996 A [0049]
- EP 0307434 A [0050]
- WO 9304173 A [0050]
- WO 9734631 A [0050] [0062]
- WO 9744362 A [0050]
- WO 9805787 A [0050]
- WO 9943713 A [0050]
- WO 9951642 A [0050]
- WO 9958572 A [0050]
- WO 02060919 A [0050]
- WO 03074679 A [0050]
- WO 2004016750 A [0050]
- WO 2004029207 A [0050]
- WO 2004063351 A [0050]
- WO 2004074455 A [0050]
- WO 2004035752 A [0050]
- WO 2004099249 A [0050]
- WO 2005077981 A [0050]
- WO 2005092925 A [0050]
- WO 2006019447 A [0050]
- WO 2006031994 A [0050]
- WO 2006047350 A [0050]
- WO 2006053301 A [0050]
- WO 2006088494 A [0050]
- WO 2007041635 A [0050]
- US 5739277 A [0054]
- US 5047335 A [0060]
- US 5510261 A [0060]
- US 5278299 A [0060]
- WO 8605807 A [0173]
- WO 8901036 A [0173]
- US 5122464 A [0173]
- US 5888809 A [0177]
- WO 120321 A [0201]

Non-patent literature cited in the description

- **ANDREWS et al.** *Blood*, 1983, vol. 62, 24-132 [0002]
- **ANDREWS et al.** *Journal of Experimental Medicine*, 1989, vol. 169, 1721-1731 [0002]
- **VALENT et al.** *Blood*, 1989, vol. 73 (7), 1778-85 [0002]
- **DUZKALE et al.** *Biol Blood Marrow Transplant*, 2003, vol. 9 (6), 364-72 [0002]
- **AUDRAN et al.** *J Immunol Methods*, 1995, vol. 188 (1), 147-54 [0002]
- **GUNTEN et al.** *Ann. N. Y. Acad. Sci.*, 2008, vol. 1143, 61-82 [0003]
- **BRINKMAN-VAN DER LINDEN et al.** *Mol Cell Biol.*, 2003, vol. 23 (12), 4199-206 [0003]
- **PLESA et al.** *Cancer*, 2007, vol. 112 (3), 572-80 [0004]
- **HAUSWIRT et al.** *Eur J Clin Invest*, 2007 [0004]
- **SCHEINBERG et al.** *Leukemia*, 1989, vol. 3, 440-445 [0004]
- **AMADORI et al.** *Cancer Treat Rev.*, 2008, vol. 34 (1), 49-60 [0004]
- **CARON et al.** *Cancer Research*, 1992, vol. 52 (24), 6761-6767 [0004]
- **RAZA et al.** *Abstract #983, 14th EHA Congress*, 04 June 2009 [0004]
- **SUTHERLAND et al.** *Mabs*, 2009, vol. 1 (5), 481-490 [0005]
- **WENG ; LEVY.** *J Clin Oncol.*, 2003, vol. 21 (21), 3940-7 [0005]
- **HARLOW ; LANE.** *Antibodies: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1988 [0020]
- *The Pharmacology of Monoclonal Antibodies*. Springer-Verlag, 1994, vol. 113, 269-315 [0029]

- **SAMBROOK.** Molecular Cloning. Cold Spring Harbor Laboratory Press, 15 January 2001 [0032]
- **PIERELLI et al.** *Br. J Haematol.*, 1993, vol. 84, 24-30 [0033]
- **MATUTES et al.** *Hematol. Oncol.*, 1985, vol. 3, 179-186 [0033]
- **TAUSSIG et al.** *Blood*, 2005, vol. 106, 4086-4092 [0033]
- **FLORIAN et al.** *Leuk. & Lymph.*, 2006, vol. 47, 207-222 [0033]
- **KÖHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0034]
- **KOZBOR et al.** *Immunology Today*, 1983, vol. 4, 72 [0034] [0172]
- **COLE et al.** Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, Inc, 1985, 77-96 [0034] [0172]
- **BERTER et al.** *Science*, vol. 240, 1041-1043 [0037]
- **LIU et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 3439-3443 [0037]
- **LIU et al.** *J. Immunol.*, 1987, vol. 139, 3521-3526 [0037]
- **SUN.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 214-218 [0037]
- **NISHIMURA et al.** *Cancer. Res.*, 1987, vol. 47, 999-1005 [0037]
- **WOOD et al.** *Nature*, 1985, vol. 314, 446-449 [0037]
- **SHAW et al.** *J. Natl. Cancer Inst.*, 1988, vol. 80, 1553-1559 [0037]
- **MORRISON.** *Science*, 1985, vol. 229, 1202-1207 [0037]
- **OI et al.** *BioTechniques*, 1986, vol. 4, 214 [0037]
- **JONES et al.** *Nature*, 1986, vol. 321, 552-525 [0037]
- **VERHOEYAN et al.** *Science*, vol. 239, 1534 [0037]
- **BEIDLER et al.** *J. Immunol.*, 1988, vol. 141, 4053-4060 [0037]
- **TENG.** *Proc. Natl. Acad. Sci. USA.*, 1983, vol. 80, 7308-7312 [0037]
- **KOZBOR et al.** *Immunology Today*, 1983, vol. 4, 72-79 [0037]
- **OLSSON.** *Meth. Enzymol.*, 1982, vol. 92, 3-16 [0037]
- **LONBERG ; HUSZAR.** *Int. Rev. Immunol.*, 1995, vol. 13, 65-93 [0038]
- **JESPER.** *Biotechnology*, 1994, vol. 12, 899-903 [0039]
- **HOOGENBOOM ; WINTER.** *J. Mol. Biol.*, 1991, vol. 227, 381 [0039]
- **MARKS et al.** *J Mol Biol*, 1991, vol. 222, 581 [0039]
- The rise of monoclonal antibodies as therapeutics. **QUAN ; CARTER.** In *Anti-IgE and Allergic Disease*. Marcel Dekker, 2002, vol. 20, 427-469 [0039]
- **BIRD.** *Science*, 1988, vol. 242, 423-42 [0040]
- **HUSTON et al.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 5879-5883 [0040]
- **WARD et al.** *Nature*, 1989, vol. 334, 544-54 [0040]
- **CUNNINGHAM ; WELLS.** *Science*, 1989, vol. 244, 1081-1085 [0044]
- **LAZAR et al.** *PNAS*, 2006, vol. 103 (11), 4005-4010 [0049]
- **CARON et al.** *J Exp. Med*, 1992, vol. 176, 1191-1195 [0049]
- **SHOPES.** *J. Immunol.*, 1992, vol. 148, 2918-2922 [0049]
- **WOLFF et al.** *Cancer Research*, 1993, vol. 53, 2560-2565 [0049]
- **STEVENSON et al.** *Anti-Cancer Drug Design*, 1989, vol. 3, 219-230 [0049]
- **JEFFERIS ; LUND.** *Chem. Immunol.*, 1997, vol. 65 (11), 1-128 [0055]
- **WRIGHT ; MORRISON.** *TibTECH*, 1997, vol. 15, 26-32 [0055]
- **BOYD et al.** *Mol. Immunol.*, 1996, vol. 32, 1311-1318 [0055]
- **WITTWE ; HOWARD.** *Biochem.*, 1990, vol. 29, 4175-4180 [0055]
- **WYSS ; WAGNER.** *Current Opin. Biotech.*, 1996, vol. 7, 409-416 [0055]
- **MALHOTRA et al.** *Nature Med.*, 1995, vol. 1, 237-243 [0055]
- **BOYD et al.** *Mol. Immunol.*, 1996, vol. 32 (131), 1-1318 [0055]
- **UMANA et al.** *Nature Biotech.*, 1999, vol. 17, 176-180 [0055]
- **HSE et al.** *Biol. Chem.*, 1997, vol. 272, 9062-9070 [0060]
- **WEINER GJ.** Monoclonal antibody mechanisms of action in cancer. *Immunol Res.*, 2007, vol. 39 (1-3), 271-8 [0089]
- **CLYNES RA ; TOWERS TL ; PRESTA LG ; RAVETCH JV.** Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med*, April 2000, vol. 6 (4), 443-6 [0089]
- *J Clin Oncol.*, 01 November 2003, vol. 21 (21), 3940-7 [0089]
- *Adv Drug Deliv Rev.*, 07 August 2006, vol. 58 (5-6), 640-56 [0089]
- The Merck Manual. 1997, vol. 92, 1059-1073 [0097]
- Remington: The Science and Practice of Pharmacy [0154]
- **GOODSON.** *Medical Applications of Controlled Release*, 1984, vol. 2, 115-138 [0164]
- **LANGER.** *Science*, 1990, vol. 249, 1527-1533 [0164]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0172]
- **HUSE et al.** *Science*, 1989, vol. 246, 1275-1281 [0172]
- **CLACKSON et al.** *Nature*, 1991, vol. 352, 624 [0172]
- **HANE et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 4937 [0172]
- **HUTCHINSON et al.** *J. Biol. Chem.*, 1978, vol. 253, 6551 [0173]
- **MORRISON et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 851-855 [0174]
- **NEUBERGER et al.** *Nature*, 1984, vol. 312, 604-608 [0174]
- **TAKEDA et al.** *Nature*, 1985, vol. 314, 452-454 [0174]

- **SAMBROOK et al.** Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory, 1990 [0175]
- **SAMBROOK et al.** Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Publish, 2001 [0175]
- **AUSUBEL et al.** Current Protocols in Molecular Biology. John Wiley & Sons, 1993 [0175] [0184]
- **FOECKING et al.** *Gene*, 1986, vol. 45, 101 [0177]
- **COCKETT.** *BioTechnology*, 1990, vol. 8, 2 [0177]
- **RUTHER et al.** *EMBO J.*, 1983, vol. 2, 1791-94 [0179]
- **INOUE ; INOUE.** *Nucleic Acids Res.*, 1985, vol. 13, 3101-3109 [0179]
- **VAN HEEKE ; SCHUSTER.** *J. Biol. Chem.*, 1989, vol. 24, 5503-5509 [0179]
- **LOGAN ; SHENK.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 355-359 [0181]
- **BITTNER et al.** *Methods in Enzymol.*, 1987, vol. 153, 51-544 [0181]
- **WIGLER.** *Cell*, 1977, vol. 11, 223 [0184]
- **SZYBALSKA ; SZYBALSKI.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 48, 202 [0184]
- **LOWY et al.** *Cell*, 1980, vol. 22, 817 [0184]
- **WIGLER.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 3567-70 [0184]
- **O'HARE et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 1527-31 [0184]
- **MULLIGAN ; BERG.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 2072-76 [0184]
- *Clinical Pharmacy*, vol. 12, 488-505 [0184]
- **WU ; WU.** *Biotherapy*, 1991, vol. 3, 87-95 [0184]
- **TOLSTOSHEV.** *Arm. Rev. Pharmacol. Toxicol.*, 1993, vol. 32, 573-596 [0184]
- **MULLIGAN.** *Science*, 1993, vol. 260, 926-932 [0184]
- **MORGAN ; ANDERSON.** *Ann. Rev. Biochem.*, 1993, vol. 62, 191-217 [0184]
- **TIB TECH**, May 1993, vol. 11 (5), 155-215 [0184]
- **SANTERRE et al.** *Gene*, 1984, vol. 30, 147-50 [0184]
- **KRIEGLER.** Gene Transfer and Expression. A laboratory Manual. Stockton Press, 1990 [0184]
- **DRACOPOLI et al.** Current Protocols in Human Genetics. John Wiley & Sons, 1994 [0184]
- **COLBERRE-GARAPIN et al.** *J. Mol. Biol.*, 1981, vol. 150, 1-14 [0184]
- DNA cloning. Academic Press, 1987, vol. 3 [0185]
- **CROUSE et al.** *Mol. Cell. Biol.*, 1983, vol. 3, 257-66 [0185]
- **PROUDFOOT.** *Nature*, 1986, vol. 322, 562-65 [0186]
- **KOHLER.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 2197-9 [0186]
- **YOKOYAMA et al.** Production of Monoclonal Antibodies. *Current Protocols in Immunology*, 2006 [0188]
- **BROCKHOFF et al.** *Cytometry*, 01 September 1994, vol. 17 (1), 75-83 [0190]

CD33 kötőágens



SZTNH-100044681

Szabadalmi igénypontok

1. CD33 kötőágens, amely humán CD33-hoz kötődik, a CD33 kötőágens egy antitest vagy egy antitest származéka, és azzal definiált, hogy a humán CD33 FFHPIFYIDKNSPVHGYW (SeqID No: 141) aminosav szekvenciájában lévő valamely epitóphoz specifikusan kötődik.
2. Az 1. igénypont szerinti CD33 kötőágens, azzal jellemezve, hogy rendelkezik egy nehéz lánc variábilis régióval, amely tartalmaz CDR1-et, CDR2-t és CDR3-at, és könnyű lánc variábilis régióval, amely tartalmaz CDR4-et, CDR5-öt és CDR6-ot, ahol a CDR1 aminosav szekvenciája a SeqID No: 1 - 14 közül, a CDR2 aminosav szekvenciája a SeqID No: 15 - 28 közül, a CDR3 aminosav szekvenciája a SeqID No: 29 - 42 közül, a CDR4 aminosav szekvenciája a SeqID No: 43 - 56 közül, a CDR5 aminosav szekvenciája a SeqID No: 57 - 70 közül, a CDR6 aminosav szekvenciája a SeqID No: 71 - 84 közül választott.
3. Az 1. vagy 2. igénypont szerinti CD33 kötőágens, ahol az epitóp hidrogénkioszerélődés tömegspektroszkópiával meghatározott.
4. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens internalizációs kinetikája olyan, hogy a CD33 kötőágens kezdeti mennyiségének legalább 40%-a a sejtfelületen marad az inkubációt követő 4 órás időben.
5. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a nehéz lánc variábilis régió a SeqID No: 85 - 99 közül választott aminosav szekvenciát tartalmaz és a könnyűlánc variábilis régió a SeqID No: 99 - 112 közül választott aminosav szekvenciát tartalmaz.
6. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens olyan nehéz láncsal rendelkezik, amelynek aminosav szekvenciája a SeqID No: 113 - 126 közül választott, és olyan könnyű láncsal, amelynek aminosav szekvenciája a SeqID No: 127 - 140 közül választott.

7. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens affinitásának K_d-je 10 nM vagy kevesebb mind a humán CD33-hoz, mind a cynomolgus CD33-hoz.
8. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens humanizált.
9. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens teljesen humán.
10. Bármely megelőző igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens tartalmaz továbbá effektor funkciót.
11. A 10. igénypont szerinti CD33 kötőágens, ahol az effektor funkciót egy F_c domén mediálja.
12. A 10. igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens az F_c doménben az F_c domén funkcióját moduláló egy vagy több mutációt tartalmaz.
13. A 12. igénypont szerinti CD33 kötőágens, ahol az F_c domén funkciójának modulációja az ADCC növekedése legalább 10%-kal, előnyösen 50%-kal, és még előnyösebben 100%-kal.
14. A 12. - 13. igénypontok bármelyike szerinti CD33 kötőágens, ahol az F_c doménben lévő mutációk a Kabat EU számozási index szerinti 332 és/vagy 239 és/vagy 236 pozíciókban lévő aminosavak közül választott egy vagy több pozícióban vannak.
15. A 12. - 14. igénypontok bármelyike szerinti CD33 kötőágens, ahol az F_c doménben lévő mutációk a 239 és 332 pozíciókban lévő szubsztitúciók kombinációja, előnyösen az S239D/I332E.
16. A következők közül választott CD33 kötőágens:
antitest, amely tartalmaz SeqID No: 1 CDR1-et, SeqID No: 15 CDR2-t, SeqID No: 29 CDR3-at, SeqID No: 43 CDR4-et, SeqID No: 57 CDR5-öt és SeqID No: 71 CDR6-ot,
antitest, amely tartalmaz SeqID No: 2 CDR1-et, SeqID No: 16 CDR2-t, SeqID No: 30 CDR3-at, SeqID No: 44 CDR4-et, SeqID No: 58 CDR5-öt és SeqID No: 72 CDR6-ot,
antitest, amely tartalmaz SeqID No: 3 CDR1-et, SeqID No: 17 CDR2-t, SeqID No: 31 CDR3-at, SeqID No: 45 CDR4-et, SeqID No: 59 CDR5-öt és SeqID No: 73 CDR6-ot,

antitest, amely tartalmaz SeqID No: 4 CDR1-et, SeqID No: 18 CDR2-t, SeqID No: 32 CDR3-at, SeqID No: 46 CDR4-et, SeqID No: 60 CDR5-öt és SeqID No: 74 CDR6-ot,

antitest, amely tartalmaz SeqID No: 5 CDR1-et, SeqID No: 19 CDR2-t, SeqID No: 33 CDR3-at, SeqID No: 47 CDR4-et, SeqID No: 61 CDR5-öt és SeqID No: 75 CDR6-ot,

antitest, amely tartalmaz SeqID No: 6 CDR1-et, SeqID No: 20 CDR2-t, SeqID No: 34 CDR3-at, SeqID No: 48 CDR4-et, SeqID No: 62 CDR5-öt és SeqID No: 76 CDR6-ot,

antitest, amely tartalmaz SeqID No: 7 CDR1-et, SeqID No: 21 CDR2-t, SeqID No: 35 CDR3-at, SeqID No: 49 CDR4-et, SeqID No: 63 CDR5-öt és SeqID No: 77 CDR6-ot,

antitest, amely tartalmaz SeqID No: 8 CDR1-et, SeqID No: 22 CDR2-t, SeqID No: 36 CDR3-at, SeqID No: 50 CDR4-et, SeqID No: 64 CDR5-öt és SeqID No: 78 CDR6-ot,

antitest, amely tartalmaz SeqID No: 9 CDR1-et, SeqID No: 23 CDR2-t, SeqID No: 37 CDR3-at, SeqID No: 51 CDR4-et, SeqID No: 65 CDR5-öt és SeqID No: 79 CDR6-ot,

antitest, amely tartalmaz SeqID No: 10 CDR1-et, SeqID No: 24 CDR2-t, SeqID No: 38 CDR3-at, SeqID No: 52 CDR4-et, SeqID No: 66 CDR5-öt és SeqID No: 80 CDR6-ot,

antitest, amely tartalmaz SeqID No: 11 CDR1-et, SeqID No: 25 CDR2-t, SeqID No: 39 CDR3-at, SeqID No: 53 CDR4-et, SeqID No: 67 CDR5-öt és SeqID No: 81 CDR6-ot,

antitest, amely tartalmaz SeqID No: 12 CDR1-et, SeqID No: 26 CDR2-t, SeqID No: 40 CDR3-at, SeqID No: 54 CDR4-et, SeqID No: 68 CDR5-öt és SeqID No: 82 CDR6-ot,

antitest, amely tartalmaz SeqID No: 13 CDR1-et, SeqID No: 27 CDR2-t, SeqID No: 41 CDR3-at, SeqID No: 55 CDR4-et, SeqID No: 69 CDR5-öt és SeqID No: 83 CDR6-ot,

antitest, amely tartalmaz SeqID No: 14 CDR1-et, SeqID No: 28 CDR2-t, SeqID No: 42 CDR3-at, SeqID No: 56 CDR4-et, SeqID No: 70 CDR5-öt és SeqID No: 84 CDR6-ot.

17. A következők közül választott CD33 kötőágens:

antitest, amely tartalmazza a SeqID No: 95 nehéz lánc variábilis régiót és a SeqID No: 99 könnyű lánc variábilis régiót,

antitest, amely tartalmazza a SeqID No: 96 nehéz lánc variábilis régiót és a SeqID No: 100 könnyű lánc variábilis régiót,

antitest, amely tartalmazza a SeqID No: 97 nehéz lánc variábilis régiót és a SeqID No: 101 könnyű lánc variábilis régiót,

antitest, amely tartalmazza a SeqID No: 88 nehéz lánc variábilis régiót és a SeqID No: 102 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 89 nehéz lánc variábilis régiót és a SeqID No: 103 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 90 nehéz lánc variábilis régiót és a SeqID No: 104 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 91 nehéz lánc variábilis régiót és a SeqID No: 105 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 92 nehéz lánc variábilis régiót és a SeqID No: 106 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 93 nehéz lánc variábilis régiót és a SeqID No: 107 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 94 nehéz lánc variábilis régiót és a SeqID No: 108 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 95 nehéz lánc variábilis régiót és a SeqID No: 109 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 96 nehéz lánc variábilis régiót és a SeqID No: 110 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 97 nehéz lánc variábilis régiót és a SeqID No: 111 könnyű lánc variábilis régiót,
antitest, amely tartalmazza a SeqID No: 98 nehéz lánc variábilis régiót és a SeqID No: 112 könnyű lánc variábilis régiót,

18. A következők közül választott CD33 kötőagens:

antitest, amely tartalmaz egy SeqID No: 113 nehéz láncot és egy SeqID No: 127 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 114 nehéz láncot és egy SeqID No: 128 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 115 nehéz láncot és egy SeqID No: 129 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 116 nehéz láncot és egy SeqID No: 130 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 117 nehéz láncot és egy SeqID No: 131 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 118 nehéz láncot és egy SeqID No: 132 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 119 nehéz láncot és egy SeqID No: 133 könnyű láncot,
antitest, amely tartalmaz egy SeqID No: 120 nehéz láncot és egy SeqID No: 134 könnyű láncot,

antitest, amely tartalmaz egy SeqID No: 121 nehéz láncot és egy SeqID No: 135 könnyű láncot and a light chain of,

antitest, amely tartalmaz egy SeqID No: 122 nehéz láncot és egy SeqID No: 136 könnyű láncot and a light chain of,

antitest, amely tartalmaz egy SeqID No: 123 nehéz láncot és egy SeqID No: 137 könnyű láncot and a light chain of,

antitest, amely tartalmaz egy SeqID No: 124 nehéz láncot és egy SeqID No: 138 könnyű láncot and a light chain of,

antitest, amely tartalmaz egy SeqID No: 125 nehéz láncot és egy SeqID No: 139 könnyű láncot,

antitest, amely tartalmaz egy SeqID No: 126 nehéz láncot és egy SeqID No: 140 könnyű láncot.

19. A 16. - 18. igénypontok bármelyike szerinti CD33 kötőágens, ahol a CD33 kötőágens tartalmaz továbbá effektor funkciót.

20. A 19. igénypont szerinti CD33 kötőágens, ahol az effektor funkciót egy F_c domén mediálja.

21. A 19. igénypont szerinti CD33 kötőágens, ahol a CD33 kötőágens az F_c doménben az F_c domén funkcióját moduláló egy vagy több mutációt tartalmaz.

22. A 21. igénypont szerinti CD33 kötőágens, ahol az F_c domén funkciójának modulációja az ADCC növekedése legalább 10%-kal, előnyösen 50%-kal, és még előnyösebben 100%-kal.

23. A 21. - 22. igénypontok bármelyike szerinti CD33 kötőágens, ahol az F_c doménben lévő mutációk a Kabat EU számozási index szerinti 332 és/vagy 239 és/vagy 236 pozíciókban lévő aminosavak közül választott egy vagy több pozícióban vannak.

24. A 21. - 23. igénypontok bármelyike szerinti CD33 kötőágens, ahol az F_c doménben lévő mutációk a 239 és 332 pozíciókban lévő szubsztitúciók kombinációja, előnyösen az S239D/I332E.

25. DNS molekula, amely a bármely előző igénypont szerinti CD33 kötőágens nehéz lánc variábilis régióját kódoló régiót tartalmaz.

26. DNS molekula, amely az 1. - 24. igénypontok bármelyike szerinti CD33 kötőágens könnyű lánc variábilis régióját kódoló régiót tartalmaz.

27. Expressziós vektor, amely a 25. vagy 26. igénypont szerinti DNS molekulát tartalmazza.

28. Gazdasejt, amely a 27. igénypont szerinti egy vagy több vektort hordozza.

29. Az 1. - 24. igénypontok bármelyike szerinti CD33 kötőagens előállítására szolgáló eljárás, amely tartalmazza gazdasejt 27. igénypont szerinti egy vagy több vektorral történő transzfektálását, a gazdasejt tenyésztését és az antitest molekula visszanyerését és tisztítását.

30. Gyógyszerészeti kompozíció, amely tartalmaz hatóanyagként az 1. - 24. igénypontok bármelyike szerinti egy vagy több CD33 kötőagénst, és legalább egy fiziológiásan elfogadható hordozót.

31. A 30. igénypont szerinti gyógyszerészeti kompozíció, amely tartalmaz továbbá egy vagy több további terápiás szert.

32. A 30. - 31. igénypontok bármelyike szerinti gyógyszerészeti kompozíció CD33-at a felszínükön kifejező sejtek kimerítésére.

33. A 30. - 31. igénypontok bármelyike szerinti gyógyszerészeti kompozíció mieloid sejt rosszindulatúság és mielodiszplastikus szindróma (MDS) kezelésében történő alkalmazásra.

34. Gyógyszerészeti kompozíció a 33. igénypont szerinti alkalmazásra, ahol nevezett mieloid rosszindulatúság az akut mieloid leukémia és a krónikus mieloid leukémia közül választott.

35. A 30. - 31. igénypontok bármelyike szerinti gyógyszerészeti kompozíció patológiájukban mieloid sejteket tartalmazó autoimmun és gyulladásos megbetegedések kezelésében történő alkalmazására.